Advances in Cancer Treatment

がん治療のあゆみ
2014/第34回一般研究助成

34

公益財団法人 がん集学的治療研究財団

-.")0$*42&%,3/+1#'#(!
­ù_

á

û

&



tLN[5"by"ºTS"fxwÜ"ÜC"íl%J?LªÎ^·RCü
Hä;O|AH6SC;"EM9I

K7Jð²B%MÂ¦;¡AT";IãUA

6ÝJAH.î@[H6SC!ÖL"üHäNäIVµ(IÄYZ[K6|g;¦´I<9Y"EMJ¢JAHn&ry.$.ÿ^O=z'AH6ZÝJAH"æIÚ=@[H6Z?JUùýI5YSC!
m¨L±L96HU"tN^Ú¸þIÝM}:;);_*L»¥A"EM.,;÷CZJÒ7½\A6Ý'$(IC;"EM9I;_M§"3Y"û±I_NM4
^8>H6SC!ÖL"EM_E/I iPS å^ñTO=MãDV±;|@["6¶LÙËAH6SC!kèXM~Ì¸)=ù¾U"?MImB#õME/L5ZJ­A
H6SC!A:A"éßMl`co{ùÉVhjkqåUl%I"
Ía@["EMÇ©¾:XM®À;ÆÐA"2³´*øÏMeÌ¸M³­³d;UÐY"è>I~Ì¸)=ù¾Mú;àsJKY"kèXM­ùI\öCQ<:;¶º@[Z0ùR^Å8
H6SC!
J?\I"~Ì¸)=ù¾N"­I

^\1JAF Translational research M´*©

PM©I"°L./vM¹ï;5Y")wTZ;_¥ÿ@_*MFTLX:MÙË;I<H<FJüA"vjU,+MD?LLc@DH`<SAF!Õ6"¹L$.@[SAF
D?MO=N"Ñç?MMónÿJAH££@[H6SCMI"?MIUX:M9¡L®HH6ZJ«_I6SC!
@H"kèXIN")¥ÿL¤A6;_¢±"qzgbem4*^-++/vL´

AH+++·/MT³´*øÏIU¬"O=M´*øÏ^gAH<SAF!pLã¿N","
+·:^^8H"±§qL+·%A;¤¯I<":vGWYOÝ§´*øÏ IDEA LUì
A"ÝæfLUÚ6^oH6SC!"9Ì¸^©AF´*øÏIN|syv{ª< Stage "3ÃÓu¨LPCZ Ki12lMoact&d&MÊê"}"¼qJÛm
IØ7T]¨^P-JAF JOIN Trial IN"»iT

fnu

i{j&M¼²MUJ.++·/M+·IýôA"~4Ø#â|¨^PGWAS ^©6F«fhò@^,"/++·M HER2 W{|Ñj^@A" HER2 ª<¨LPC
JAF´*Ì¸INt6,"
Z trastuzumab M¥Ô<MÊ,"·O Stage T];_LPCZâ|ªÎòÁJAH
CEA mRNA MÊêl^ØGH6SCMI"~Ì¸)=ù¾IM=U!M°µJAH
©"gI<H9Y!@XKZ|g;±Q@[SC!
@H"×N"=-0vj$.ÿMÌ¸=^SJTFëòIC;"x"¼"G®F¨"a]¨"Þr"¼"½¨"<x{p""MÈ¬"¼l%JP-K¬;O¯L]FY"û±?{^6"v9Oo*641B5*>3:6"s{.:wu9

-"0E

U87C`B<X*63!
\V9"FTMhtaP60q->24_}:a"Ja"L=y[P6+r
98A>24ixy[DG~=9y[DG:wu"Z9;ekc#t&($60
gbC`A>24WujSYQ~:nz]wu"K|HNf:Ixwu9?m,@odp2l/>3!
t&)'R'%

%#"!&$
m$Ûhnz

hnî

Å

Ù

ú

C

y2£^êO=2£Ê@È;SA!
ÀEÄÐæÇ»^,'ª;9L@J5ZS@E7".Ð(*ÿô6YQ^KÆPTL@"
KÆµL@J,ÿfýOº²v!K1[<L7u]Z"O.Ð)*ÿôXZ%»OA@2@+I4&^AØ@J©éA[<LLNHJ5ZSA!SE.Ð)-ÿô6Y"Ü{¼J»P
r1Q¼J,ÿ^y@J2[<L^Ê¤TD¡Ou4S@E!
r1ÍQ"7ÿôQ®ÿXZ*â4J+0K@E!r1ñUÕZQ/*(þ"DPr
1ÃLP`c$Q¶<XZÝJPÛhnOá)@"¶Ü't^@J2EF8S@E!
¶Ü'tKQ"×æ'tPåO"ßæ'tK©ó^52@J5ZSA!DPx^¶<K¾@"[('(.þOç*0{m$Ûhnz^|§@"Ûhn7Èg6Y(èBIP^¿,O

HJÒO't^

2S@E!<PÛhnz¶OQ".ÏRø>Ï^H@"kWFB^O@"/ä@J5ZSA!
DPx('PÄÐ¼J»^US@E!ÄÐ^¼J>\[3Qí2£LN[6V@\SC_7"(ÿOx^#&@Jï8SA!SE"A\EQ"°6õ7_ad
b$OÌÚA[<LONHJ5ZSA!
ÄÐ^¼J>\[ØÓ3O52@SA!
P-^#&>\[«Q%7_¾}ò¹I­ëÄÐ&P0Ä^ûE³^>@Jï
9X352@SA!¥{SKPÄÐà~Q-s*(''8qLNHJ5Z"7_¹IPO?
GHJ2[VPLÌ¯@J5ZSA7"7­ëQp4ËKAPK"acknowledgement ^)@EP-^

@Jï9<LQ"ÁDNi:^·HJ5ZSA!ISZ­ëPÔOVNZS

A!'t^¾UJTSAL+0P3GÈP*,P(QùóÍ6(ó¦L23¶K"%ÉO't
P¢2P-7ãHJ5ZSA!DPíKÛA[EU"©é>\EL23<LQ"Î%LVP-O@Jï8"acknowledgement ^):Jï8E2L4J5ZSA!´ËL@JQ"¸{PÛhnzK",ÿfýOP-^#&@E²ÖOI2JQ(ó^uóA[÷^ðe@X3
L±HJ5ZSA!¬SKO"acknowledgement ^):Jï2EP-Q5M­ëOü2J
5ZSC_!¥{¼J>\E3Q¥r1>\["PjOV"acknowledgement ^):EP-

^52ì@SA!

¨ONZS@E7"ÄÐ>\[('=PØÓ3"¥{Q7öO5UKL3=?2SA!SE<PÞÑY@2ØÓ3^=ÌÚï8S@EÌÚ»P}î"l}*RN}*P}*î"wî"(oî"ÂîNMP3#O95MÊ@È;SA!
fÈKy2£^½]ZSA!

" & ( * # ! % $ )'CÒ2>2?- ######*¤Ø



¦

¬

û

Åo÷ ###########fòÅ`gr!`gØ

¯

Â

ã

%

&11Cmethionine PETPRM s À9@Bë 1 p ª9.1B ### þk/A¥8BïÛ=:î

Bevacizumab ,ù:¦,ñjómù:v+

XGcma,7E
XGcmTRa(*)"_P>42&Üd!¸¼Æ+Äz9Í3BPLN["IXMDJ\Cj(24 ### ¯¶-°j(¡a% ## (=q8KX5+5e`^625;I&ïQEYJIÙ×z9Í3BÇ·lw,ù7lwø¨Ã,ù: ### ¯­ÆÕ¥ß'9@BÇ0¶2,«wÚ¦,:-°Ð]É£

w ## "¿~ ##"$#'@93lia,
O0642&ýijàsÀ9|5,4æöª0:REGW"H":tï ### üé ###!

LZ\X5+5e
U<425;I&KRAS eÝ¢ÿ¾:¦!Á®ôê8¸!ï:×!Ù×z9Í3B)¥¦, ### 726: Cetuximab$q2w%+mFOLFOX6>4; Cetuximab$q2w%+mFOLFIRI,ù:-°Ð]É£ <¦,nC&Ë3BREGW"H":á

Þ

Æ

Ñ

Ù

¹ ##%!

ì ##%%

Îº ##&!

[:X5+5edVa,?-!Jr]2&ø¨Ã¦,.C#3Bï^¼ëª09Í3B²¨:b ### ØÑÂ
9y3B

q ##$%XGHmX5X5,+5@92?-JrSC5&»c½³9Í3BÈ}FYJZVFK\qè:" ### å_Ì¼9Í3BhCá3B-°£/bHmX5X5,+5@92
aWj.SC]25&ç¦¼Ê{^¼ª09Í3BHLAðÔâ©Êxú ### Öd´ä

FYX5+5edVa,
D5+nQne&ü±¼+úY\Sª9Í3BTHPCOP(*,ù:uÏ-° ### õÐ]É£µ ###'[hX51p+5@9M
oNJr5fk&KIF)'A73BRNAÓí§$)UTKO[IK\: ### Ñ¶2z¦,=:j(

Ïf/ ##&)

gBAm$%&a,?-Jr]2

1 U ¼ G D - M J

1Cmethionine PETPRM *.#%&/5)-

11#!"& Bevacizumab 42$,40'1(2$+3<|&% )'(*ùNP63@LËþ®þK&ÃCè5? Bevacizumab D¶B1òzîABP-¢Ä°4R:1"

ûÃJCè6Q¼G§ÿïA5?bWfV[c\_k`#dA5?DB4R?.Q MRI 1 Bevacizumab D
K

@E"MRI NPLÛCKÃDÃJ¯29

õT!w6Q 11Cmethionine PET T½C"÷áCöñÊET(5 Bevacizumab DK

Ã¼G@E%~g`iaWA5?'0@-Q:K"6

Ã¼GTñC¸}6Q3AT¹J:!9D"MRI @EA¡6Q3A1@2B0<:ÃJDâmT 11Cmethionine
PET BOGC Parametric Response Map CNP¸}@2"4OCE Bevacizumab CNQKÃD&,"=IPãv&,AÕÉ*@D¼G!zÙDr.T;O0C6Q3AL@2:!

# ! $ "
$û%KÃEìyÜæ1=(+lA#ÑCA¦'HB£þÙûÃJ@-Q1"63@E)'',ùCag`#j$TMZ%1-¢Ä°4R?nC"¼GÚÞ1'7äB1OL@pCx
í5:!K

ÃEÃJ6çDÅoCÕÉÙCûàÓTÔ5"ÛÑBûàÓT5ñC95?

úñCü5B1O×ó6Q!¥²D$È¼GEÂÇCNQñBÃJD¤IAÇ¦D
TMZ +B|/Àß¼GBOGC9RCt2å2©SRQ TMZ CNQq»G1@-Q!3D
N/B¼GT·63A@ìyÜæE=()l0O(+0HAxí5(%"ÃJðÆÂÇD±Cúñ MRI CNQû"¿ú%~"µak^jáCNQý¿Ößq%~"4OCEÝ|ÂÇA.<:ûú{æÂÇ1þó5:3ACNPÜæìDÁDÜD¿$QOL%LÏÍ5:!
505B1O")'(*ùI@EfV#\chXkA5?¶B4RQ TMZ nCñ­C>.:]ZkdhXk¼GEæ²87"KÃ1 TMZ 'zÙC®þ5:ÐªDêé¼G>

1æ²5B.Ò@-<:!Bevacizumab 1®þKÃCè5?":âmTxí48Q

A./.« T­C)'(*ùNP63@LËþ®þK

ÃCè5? Bevacizumab D¶B1ò

)%zîABP-¢Ä°4R:!3DN/C"]ZkdhXk¼G1K,F5.s0@"8;C Bevacizumab DKÃ@ï4R:ºEëÃ¼GCè6Q§C=.?ñYebk

\145.Ò1å.?.Q!Bevacizumab DK

Ã¼GCè6Q¼G§ÿïT¬øC5?.QDE"ûÃJCè6Q¼G§ÿïA5?bWfV[c\_k`#dA5?DB4R?
.Q MRI 1¶B@2B.ôC-Q!=IP"Bevacizumab T¶B5:ÐªCEÃJ¯2E´
Ì4R?.B.CL00SO7"MRI @EÃJãv§1Î¾5"-:0LÃJ1¼?4R&ë³)F&u¨ë³)FÚØ&]k_#ûÖcYQ[f PETPRM u£AHK´ÑtA§9K`\TUb_ÍrBºo2<2BH1@ psudo-response ?013¢8K!5BH1@ MRI AHKs¥ºo3³70<F"©¨¬@Í¶lMqn9K¿ÀBvµ3¹Ê>/K!Â
xAÑtBÐÁÃ­M¶k9K C-methionine PET

>C"MRI HJG¡

MA"±s¥A¯¬ÌM

+%
(,%

11

¼p7 Bevacizumab BÑtÍM~z¬Aqn9K5?ME<!
!

"µÑtA§7= Bevacizumab ®È¤@IDA+R#e$+g%A:L;L"¦
j MRI @IDA 11Cmethionine PET M7<!A Bevacizumab ¤B 11Cmethionine
PET Ms¥Ç7<$)%!s¥ÇAC normalized mutual information algorithm-%MÉ7<!5BH1@s¥AÇM15?>"Bevacizumab ¤Bs¥M voxel-by-voxel A¯¬A·y°>4KH1A@K!6IA"matlab ?01Sf]d#X#>|7<
W^ZOPNMËÉ7="{Îi$ROI%²BwaRVe> 11Cmethionine 3ÆhA/K0Cªm7<2M«7":BrMs¥n7<$
sponse*%!±s¥M Parametric Re-

Map ?ÅÄ7< !»¾M&¦j»¾'?&¸¦j T2 }­»¾'A½Ï7":L.%

IB»¾>B Response index M·y7<!

*! Mutual normalized information &.#$'+-)*" Parametric Response Map %(,*

0 P z ® ? , H E!
¨_O(¯?s3"

Vg±~>4:vo;18!&¯@s±^~"'¯@sVg±~;,98!
Illustrative case O{5L!+)t?s±^~¯;,L!MRI ;@ Bevacizumab>IKX¤¦0BCb>|480"Bevacizumab z®*Q#Sª; MRI @c_;,L>GdNJ6"f= performance status$PS%?f=V[O184"'Uim>k¤w48$(%!11Cmethionine ? Parametric Response Map _;@"Bevacizumab >IKX¤¦@©> 11Cmethionine ?ZOFL2<0;180"£X T2 pe¤¦;@ 11Cmethionine ?}KqE­?¦[OF=/98!3J>"Bevacizumab u¬>@FJM=/98"8= 11Cmethionine p¥O`5L2<0;1"2M@ Parametric Response Map _;@91K<\x[3M8!w§y>@¥W>hX¤¦O
FL2<0;18$)%!2MJ?h]/J"MRI ;@«j5L2<0;1=/98~°?
VO 11Cmethionine PET =JA> Parametric Response Map >IK\x[;182<0{r3M8!D8"(¯>.-:X¤¦<£X¤¦? Response index O¢a5L<"
X¤¦;@z®>¡Y48'¯;@©= Response index ?OFLG??"£X¤¦?;@ Response index @BCRTO{48!2M/J"Bevacizumab @X¤¦>4:@z®n]0,LG??"~°¥;@"7?n]0l;,L2<0{r3M8$
*%
!

-!

-"

02,4%3+)'1*

1*,4$/#& Parametric Response Map (.

4

aWRZb PETPRM v³AJMÐïu¤A½5M_[SU`^ëqC×n%!

')("# Response Index $&"!

Bevacizumab åk=CëqÒÄD MRI 0Ú°y=*M7GA1OG<Î4+r¾>
3NM!xÂtº$DWI%I~êtº$PWI%Pçå47"Bevacizumab AJMïu¤CëÓj®×n0FKN<+M0"ÄÆ@Q\XbTCyéD=1<+@+!
s#D"2NE=Aïu¤CÙè{Æ@ËÁPH9>H°yAÓi5MCD 11Cmethionine
PET =*M>Å4<17!2ND"ÄdÆA¢3N7¤î¸«>tºPÕzÉ47
q"­CJ,A"¤îàãÇ> 11Cmethionine C¢LF0Ã·Æ@°¹P

5>+,qAH>;+<+M$­'%!
2CJ,@ 11Cmethionine

PET CÑCtºl®ÏPçå4<"á=D3KA Para-

metric Response Map >+,£ßPÛo5M2>=JL±ÇC+"}Æ@tº×nßC
yéP¿¯=17!2CJ,@v³PpÏA5M7GA"á=DÌ¡Ctºv³V]YP¯4"gÔì¨=çå3N<+M Dicom tºPÃµv³=1MJ,AÜ4<+M!
¯3N7 Parametric Response Map DtºÍhA4<"Ã|ÆA?CÝd0ëAÓj4
7C/P¦=1MJ,AÜ4<*L"¯tº=´ÈAØ¦3N7ÝdD»cÝ"²ÈAØ¦3N7ÝdDëÓjÝ>4<tºl3N<+M$­(%!
2NAo-<á=D Bevacizumab AJMïu¤CwÙÞ":EL¼hÙÞ>¬§Ý=CëÓj®Cf+PäK/A5M2>H=17$­)%!¼hÙÞ>¬§ÝA.+<ïu¤
A½5M Bevacizumab CÓj0e@M2>D2NE=ÀKN<.K6"á=G<äK/A@97ª=*M!784"áDâ8&í> preliminary =*L"3KA©íP¥B<á=ÊKN7m¶P3KA@HCA5MÖæ0*M>-KNM!

" & ' ( # ! % $8"Cmethionine PET '7C4@A<(:223!!

8# Parametric Response Map 19B65,.-*+)

8$;0>?'=;0>?&( Response index (/%5

LFCGM PETPRM RZ=?A\cQX=[8AJHDEKIVbUP>^O

6! $ # "
_TS4@ Bevacizumab =?AcQX>Vb]NY^O=32: 11Cmethionine PET B
a29 Parametric Response Map >`aYBW87<5;69!
&%)&Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005$352%10&#10/'1."*&Friedman HS, Prados MD, Wen PY, et al. Bevacizumab Alone and in Combination With#,/++'
Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 2009$27%*0&,("+&Kinoshita M, Arita H, Goto T, et al. A Novel PET Index, 18FFDG11CMethionine
Uptake Decoupling Score, Reflects Glioma Cell Infiltration. J Nucl Med. *()*$53%))&#)/()'0",&Okita Y, Kinoshita M, Goto T, et al.%11&Cmethionine uptake correlates with tumor celldensity rather than with microvessel density in glioma : A stereotactic imagehistology
comparison. NeuroImage. *()($49%,&#*1//'0*.
-&Arita H, Kinoshita M, Kagawa N, et al. ))Cmethionine uptake and intraoperative 5
aminolevulinic acidinduced fluorescence as separate index markers of cell density in#).)1'*/"
glioma : a stereotactic imagehistological analysis. Cancer. *()*$118%.&.&Veninga T, Huisman H, van der Maazen RWM, Huizenga H. Clinical validation of thenormalized mutual information method for registration of CT and MR images in radio#..'/1"
therapy of brain tumors. J Appl Clin Med Phys. *((,$5%+&/&Chiba Y, Kinoshita M, Okita Y, et al. Use of 11Cmethionine PET parametric response
map for monitoring WT1 immunotherapy response in recurrent malignant glioma. J
Neurosurg. *()*#)'0"

7 ] é  K 2 U Q

7?3!:7;=A<5&>$'/,.1"*0-)+2(4@#%96B84@
ûà
&%

)

)5íLT7]J5:YT#(÷e¤[Ku~ihGDÜv6WK iPS ÜvZ#¤[u~ihJè2\Äô>"°A}Þ\ 3ET#Ñ7]ÞF298­KUãqln$f\ø±7]2Y3L"}
Þ7ªñ2\?YK¡JT«?Y<G&|u~g{xg#ø±'F'²é
A!T27]\KUãqln$fK0ËJ

7F8I36G=Q>

IïK#}ÞI3AR"<Kf=K´KüOKJLåCE3I6CA!yÃ·FL"7]K¨Üv2\]t?YÜvìÅ¾\'²}Þ^li`¾Kî|G>"°AKsnü"á eIÕn\
wm_fh\

3E@KUãqln$f\ø±?YARJr`c`tb>î3oo6\XÕ>E'²Ìs}Þ\ÒX×QG34hf|$pg¾\¥>A!@<FìÝJy£cJ¯D3Asnü eIxIÑ7]Þp

}Khf|$pgJEYQ=ZA}Þ\3EüÃ·\¿>"WKKýaKSG"©ían|$\

â>A!

# ! $ "
^yJ5:Y98­K©.L¶ÀJ&NE5X"ÔT%çKq"PSA G3C
Aðw$d$KZ_IHJVY*J³õKÏ"Jg3"ØÊS?¼Ï7@9<G7==Z",*,*bJLL22ð©+GIY<G7-Q=ZE3Y!Çß"Ùé7ú7ke
I,Ó2#T298­JE>EL}nJVCEL2v}z\¸1PF;Y]oiu7Ð9Ó[ZE3Y7"@K<Í±¬LÈWZE5X"C9KþJ53E98­KÛd\aR"¸1RÑ298­GÉMZY$GGIX"@K#ÕÎIïE7I9"4{ÊLºREÆ>3!@KOFoijei}L"¢J53E¸1RÑ298­\E!G>A{kyh¦æÅ&TAX-,0æÅ'F4A±¬KP7Âÿ=ZA~KÑ7]é#§
uF"ÇßFL/OF"¸1RÑ298­JE?YjöéG>ENl:WZ"Ð9ä
+'!ywJ53ESÖ]©í\E!G>A
Ó=ZE3YJåCE3Y&0/mg%%-(.òz'I>æÅµN TAX-,0æÅKÁJ¯D3E"¸1RÑ298­JE>E¢GY
FKoijei}KáE5X"

7,**1b6Wa=Z"¸1RÑ298­©íJE>Ð9äÓ=Z;2K¥>AÑ7]éF2Y!>6>I7Woijei}u\äÓ>ES"øé6W"2Y3Lé\»Xr?4BJ"éRÑ2#Ñ7]éF2\ê?V4JI
X"@K4{Ê:ÎSÈQSF"oijei}uJE>éRÑ2GICA#Õ"ywJ53Eá

eI

I}ÞLI3!BJ

I}Þ7I3AR"+DùÄTüÂÚM

6W"oijei}KVkeI#Õ\ú3E"Î7ÈQSF2XI7WS"oijei)½´óH§§m i`®§¹ë

8*{#ã¸èðSîGø;Tlfhv%_rgZawWO:>âXÜO

tH.NW¨ö;T2"Z`YG{¸;TïýÇ:2F/H3"°ÂH3¼Hç'¶è
ðSîGø;Tice^ctUC²Hã¸:>ðSîÑ8XGø;T~UH°

C.

T!
yÝHQ0Gç'¶èðSîIM²3¢NB:VC"=HËUCIG?FõC4TC
I/&F5"½²"3¼G1/BOÑHó3Mô8UB1S"Ð(GOû4FüD
F@B/T!7H>N"ice^ctGQT¶3XËU'¶èç'¶èðSîGø:"=H'¶èW¯Ò:"ùèWº<8<T7DC"¶3XÁGø;TÔèW;8<"ice^ctUCHËUµWñ;T7D3C4T?OKÁH,Þ33E8UB/T!
°Â"¶3XËU'¶èD3XÀDDH¤3$I8UB/T!3XÀDDI"3X
òá"C"êßòáG16TòáÀDHQ0G"òáW¿·!;T4WWÊAÀDH7DC"
ÀDèYp%]%W6°:B/T!3XÀDI"¶3XËUGø:ùèWÊ@B/TD
8UB/T3"=Hùè·ILDXEH8UB/F/!3XÀDGø:µWÌ;KÁ
3.UJ"ûALODäÃ8UT3"ðSîG16Tmh3XÀDèªG1/B"LOF
Î¬sgt3F/7D"M>ÀDYp%]%H6°ì3:Ö>F>N"ðSîÀDW9(D;TËUíTGA/BI"Î¸.T/IÎ°4è3F5@98U>àúC.@>!
½MC$I"ðSîHã)r]jbqHH2R"âËUíTHSWIÅ:>ª
G×É:B4>+'(,'!M>"1GÀDHªG1/B*ÏÄHæ³3ÀDèH0#|ÊGØPC.T7DWB»:B4>-'(*)'!=HYHªH"C"ÀDèYp%]%C*ÏÄC.T OCT4 H6°3"3XÀDèDY;T7DG$I:>**'!\%nwd%aD:B´8UB/TmhðSîH}+Ä6°Hg%eo%aW#Ù:"ÀDYÄH}+Ä6°Wì:>D7V"OCT4 H6°3"mhðSîòáHêßðSîòáQSOðSî
HòáG1/BLzG6°3¹/7D"M>"1G¶3XÁGø:'¶èWÌ;*{èG
1/B=H6°3"¶3XÁGø:ÔèWL;T±¡èðSîG7:B¹/7DW«Ù:>!M>"$ImhðSîòáG1/BO"¿63÷/D8UT%>¥ðSîP"¡Úã¸G1/Bþ5uotC OCT4 H6°3¹/7D"M>"ice^ctËU²H3
XòáG1/BO"þ56°HuotC OCT4 H6°3¹/7DW2:B/T!OCT4 H
6°3¹/ðSîI3XÀDë=(xè-3¹/7D3äÃ8U"OCT4 H6°3¹5F@B/TðSî3¶3XËU'¶èDY:B/T7D3Ì¾8U"OCT4 H6°3¹/ÀDÕÿWËU9(D;Tz3HR2GF@B4>!=7C"OCT4 H6°3¹/ðSîÀ
DÎ¬§W·!;T>N"mhç'¶èðSîÀD&DU145'WO/B OCT4 H6°
3¹/ÀD£&DU145OCT4H'W>Q:"ice^ctHÔè7È¬WÆ¸:>!=H©
"OCT4 H6°3¹/£&DU145OCT4H'I"=0CF/ÀD&DU145OCT4N'G7:B"ice^ctGø;TÔè3LzG%:B1S"ice^ctUCGø:'¶è#ùèW
0:>ðSîC.T7D3 in vitro 1QK in vivo G1/BHR2G:>!8RG"DU145OCT4H
Ik%ip[aG16T8Ó[H¦éROÛF/ÀDåC¹5"3X®è#3XÀDèO¹/7DWHR2G:>!7Hice^ctUCGø:ùèW0:>"¹/3X®è#3X
ÀDèWL;T OCT4 H6°3¹/ðSîW"­H DU145OCT4N ÀDH¦ÍGJ;7DH

0 P § ä C * I F?1LÜ¡0*ME"_[\V[lC

9«µO|Ñ?1"_[\V[läÖ0Å­CJ,B

x0Ì5MLJ,BAL@³£5M:!4CJ,A~ÊB=1"_[\V[läÖB¿7
L«µC­t0wËµOÝ7LÔÜ¡OZWk%`pX7L4@@6:!×CrÄ¥ÌODNAhSWnRmSB>{·6"rÄ¥ÌendQSlOÍÆ6:!DU145OCT4HCrÄ¥ÌendQSl/K DU145OCT4N CrÄ¥ÌendQSlBÓ6ÈLÜ¡0*ME"âç°D0P§äÂµO}»58"0P¡C«µO­t&kenXjipX'?1L@-:!94?"ConnectivityMap&Broad Institute of MIT and Harvard 0¢¶
6:rÄ¥ÌC]%\f%Z?"Þ$A×BÞ$A½ÜO¢ß58>Ót7LrÄ¥ÌOÚàÃB{·6:HC'Oáß6>"4MKCrÄ¥Ì/K"DU145OCT4H O DU145OCT4N
BkenXjipX6ÈLÜ¡@6>´ªæCÔÜ¡O´âÃBÇÁ6:!©

B in vitro"in vivo ?"4MKCÔÜ¡C,;_[\V[läÖ@CÒß?ÝßµO¨7Ü¡O<3L:GB"ÔÜ¡CZWk%`pXO¦6:@4N"y0CÉ±å¯B.+>"b^)sB¿7LTSlZÜ@6>å¯°2¤ß5M"q¼µ0Bã5M>+Lkackp&®ÐÙ#YgUZ'0ÝßA­tÜ@6>ÇÁ5MÕ6:(('!
kackpD¾Cºã¹×Oß+:"ÇÞA¢u¸@o%Wdn%Oß+:©B.+>HÝßµO¨6"0P§äÂµ@0P×µOÈ6:_[\V[lÂµºã¹OÎÃ@6:§ä@6>ÀÓÝßA"b^å¯?©

B¤ß?1Lq¼µCã5M:ÔÜ¡?*L4@O¬6:!
94?Øå¯D_[\V[läÖÂµºã¹B¿7LkackpÒß_[\V[läÖCÝµ@q¼µCÏvOÛÃ@6>z5M:&²('!

"!

ð$Ó®×Ý6ÜJæ@Slgi{&^thXb|U4?CÑ 9Ê4

10

#"!$%
%&"#%òJ86F"¤Öí­×Ý6ÜJæ?Fjcd]cx8(U¹®?CÌ:K7
DK7DÅU*C@¾!
,#õ¿ö»J.+³Î41³+*K¾!
-#õÛ/&ÇJÆ-@S¸:5R"Æ-:G;S¾!
.#!5ÞÐîJÝ6Ü:VHÒê>TC¾!
/#¤Öí­×Ý6ÜG5S=H:ú>T"jcd]cx8(¬Jâ
â

?C¾!

HLK6AT9UúOCÏ¯~§Ù PSA K-;äÎËáÒêJ8<S RECIST ýêJPS PD
°a|fáÒêJ8<Sð!ßK/Q9IèNCLÑ!ßKÄ«0#PSA ë:-ÎK¾!
1#ºªìJÝ6ÜJæ@SÑ¼8:¦>TF6I6¾!

2#Easten Cooperative Oncology Group(ECOG)performance status :+NCL,G5S
¾!
3#¼ªÚø·"¼ª%é·(½,éò):,-ÁÎK2.:çG;SHýê?C¾!
4#Jò@SÂ%I§"ã¡MÔûU1@S¾!
qu_zn|

4#+g'dl Î"ü§¢.+++'}l§Éþ

20+++'}l Îànwxn|-#
0*ULN AST ¡M ALT-#
0*ULN 0mg'dl §Ù^yWfk| ,#§Ù[wZs.#0mEq Î§ÙWxor|.#+g'dl ÎåK9Ê¨²ëJE6FL)îJ CTCAE Grade,UÅH@S!
,+#õ¿ö9Q¼ª0ñ3À7¬NGÿùU®7=HJõ?F6S¾!
$!"#%)©£KæÍ¾KÈÅUJNHOS!
~wmnw|KØ%NCLåK­ZYxb0(Wa^znx"\|a^znx"nevn|ó)Jæ?"ÌKK5S¾G"ºªÚø·:#ïòHýê?C¾!
Ý6ÜGÃ÷I¯'ÌU1@S¾!
ô×KÃ$U1@S¾!
«´åK¼ªJµ?F6S¾!
BKå"¼ªÚø·"¼ª%é·:#ïòHýê?C¾!
`|pxÕ8PMBK¶Ä±¥!

5 U È F I / N L

11v,*<û!!
wª

'H¤JÐô4~H30DçDæHò<Dd`a[`qF95Äµ;S"¥öHßµ5,MPS"d`a[`qú²ãçDæFGQ"4B":GÕÅ¬H"{/GÖHá!
+61%(4&$+#2)1%(4? ° ã$PSA °$-*)zØI­Ô"
ê°C'ìù/47T?=RÙ¶(RECIST HÏ03y è ã$ÞñÓ«"GÕ©º"?Æ×

QOL 3$Í QOL ÷º2

5Ç=ü$èäî'OS("Ê%|üäî'CSS(";ëxäî'PFS("§#+öl&Z&I7
5-0'*, "!3./¿Ñ¹¢$ª'H¤JÐô4~H30DçDæHò<Dd`a[`qF95Äµ;S"¥öHßµ5,MPS"d`a[`qú²ãçDæFGQ"4B":GÕÅ¬H"{/GÖHá!,*+--+,¨OQÿITÁ<"®½KEáHIË5
Yucp&;SD3Q"Å¬¦íöE/R!
&'¸%J"5·I)ÚGÕH30D"hc.£Hò=R²WVq_>F<DGÕØ±7ÀA;S"yèã5HD;SD0Rpgipu5"d`a[`qF9ú²ã#¡âú
²ãçDæHò<?AãTÉ=>¼E/R9FT«Ñ<@5"pgipuJ"hc.£
Hò<Vua&jXsuF9FI6A>F<DHGÕØÀA;SD0RyèãID;S@>¼E/R@M"ïHÈF9IG0d`a[`qú²ã#¡âú²ãçDæHò<"1ü
H#*5/GÛ>¼E/Q"d`a[`qF9FI6A>F<Dô7?AGÈFåE
FGQ$RF´2PS¸¯IGÕªGª

Ißø5ó;SR!¸¯J³Hcou_r&^neq

T0ý;>"(ÈãçDæI'8=R}þÂfbct&\TÒ#pks]om=RF01.HC0@"&éü4BÛüGÛÈFåEIDF"?IGÕAT=ü
F<@ª

Tàß;>D06@0F´2D0R!
! $ # "»¯H":GÕª

T:B0@A6"ðôG:ÃT0@A6K<@"5UÎüÈFª¾õI@HÜÌÝ<Ø8K=!
(%+(Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus
prednisone for advanced prostate cancer. The New England journal of medicine 2004 ; 351

NB"IFJLPKD5M36>;=@$9?<8:A7CO24HEQGCO

12

%15&
#)-(*')*!
*&Kosaka T, Miyajima A, Nagata H, Maeda T, Kikuchi E, Oya M. Human castration
resistant prostate cancer rather prefer to decreased 5alphareductase activity. Scientificreports 2013 ; 3#)*.0!
+&Kosaka T, Miyajima A, Shirotake S, et al. Ets1 and hypoxia inducible factor1alphainhibition by angiotensin II type1 receptor blockade in hormonerefractory prostatecancer. The Prostate 2010 ; 70%2&#).*'1!
,&Kosaka T, Miyazaki Y, Miyajima A, et al. The prognostic significance of vasohibin1
expression in patients with prostate cancer. British journal of cancer 2013 ; 108%10&
#*)*+
'1!
-&Shirotake S, Miyajima A, Kosaka T, et al. Angiotensin II type 1 receptor expression andmicrovessel density in human bladder cancer. Urology 2011 ; 77%4&#)((1 e)1'*-!
.&Kosaka T, Kikuchi E, Mikami S, et al. Expression of snail in upper urinary tract urothelial
carcinoma : prognostic significance and implications for tumor invasion. Clinical cancer
research : an official journal of the American Association for Cancer Research 2010 ; 16%23&#-0),'*+!
/&Miyazaki Y, Kosaka T, Mikami S, et al. The prognostic significance of vasohibin1
expression in patients with upper urinary tract urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 ; 18%15&#,),-'-+!
0&Nagamatsu G, Kosaka T, Kawasumi M, et al. A germ cellspecific gene, Prmt5, works
in somatic cell reprogramming. The Journal of biological chemistry 2011 ; 286%12&#)(.,)'0!
1&Nagamatsu G, Kosaka T, Saito S, et al. Induction of pluripotent stem cells from primordial
germ cells by single reprogramming factors. Stem cells 2013 ; 31%3&#,/1'0/!
)(&Nagamatsu G, Kosaka T, Saito S, et al. Tracing the conversion process from primordial
germ cells to pluripotent stem cells in mice. Biology of reproduction 2012 ; 86%6&#)0*!
))&Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K. Identification of drugcandidate against prostate cancer from the aspect of somatic cell reprogramming. Cancer
science 2013 ; 104%8&#)()/'*.!

9 [ ¬ ? J 4 R N

13

4I-*.,+FE2&B$)@=01MK%
01J8>MK':?D6HL&()@"<#!91G7M'N;C/A53ºÏ&%ÜJ³ï¬?EKv

*ñr"·¦ýFP¡=Ha\d`]·ÅëêZß¿F>"vñrËZ4ïF>B×Äz?-F·¦ýËZ4ïF>Bz+®Ó?-%CRT&ZµÕç«õ:?VC¼
ámÙ©Z}>B!ß¿K R0 Ñ¹{üH cStage mny%ëêÔE"gÇë,/oÀMBKÛ,As,oÀJdfbÒñrh-0-(-0.dfbÒñri Circumferential Resection Margin 9,mm oùjÃãô3oÃEG6Ipæ>G6xÜJðw9H5kÝÚIÂ¶lëê1¨/I0mm oÀÂ¶"J5@
W8Z2B?¾DF>B!mFOLFOX6'Bevacizumab 1^$`"S1 (; CRT 50.4Gy Z
Z§

5"¥¬°µ>B!primary endpoint K pCR =F>"9í¾DÉK/.DF>B!-+,/û2ªòE×¾DJóEZ±>>B!-+,0û/<X"×¾DJ¬?9È?V9íE4U"<Wr

I primary endpoint Z"{üFHV¤NE4V!×Äz?-F CRT Jç«õ:ISVBHµÕ¬?KÊïIP*£K»H;"0C¼©JqK¡5!

# ! $ "
y%ëêKàêJèEP÷I9$@JBO"µÕz+®Ó?-%CRT&ISV³
ï¬?9

YWV9"·¦ýK»?VPJJv

ñrQÎÜ99Ö>H5ò95â

FHCD5V!MB"y%ëêJ°µKÁ²9à:;µ¢(¾9Þ5BO"µI´&H)¸z?-9úUI;5òP5âE4V!
YWYWK<WME"y%ÅëêIß?VµÕ CRT I0.ø­JÛ,ÍZþ6à°µZØN¢YAV<FE·¦ý1)F@HÌÐ9öTWV<F"t,EväøIÿLDìy>H5<F"T4"N23"ëêÑåµZ<?VÅ

ñrK°µHGEK·¦ý=-+)oÀ"ÎÜ=/+(0+)îôF9$@E4V<F"=TIy%ëêJ°µK¢(¾9Þ5BOµ)¸z?-97/>8

7H5<FZF'#~ý"ID*£>"<WTJ¾D

,&
(.&
!
EKSUBHµÕz?-ZOBe_cf9!<E4V<FZ¯é>D:B%Æ,&*9[~83#u½z|ædXha\ÕÓIÍ=Tº<3­Ø¨þJ"´ÏnÊ¤

14,**,ãqJ¯Æví«ÅþîßâIQS"@UqÆJÎ¬¯Ðá¨þIçM"±æüK0)LÖu<A7"tÙrüK³<H6BA!
&¯¢ /1m'/"7)% cStage '!(65,$4#&.3*+8-2:9%01½|ØIK"YZ^hegblÝJ!Hõ

W CRT Lx5DÞ¦Üø<AS"CRT W

V> FOLFOX HGJÈ»vþîJNW¯ÆÜø=Tj`fl7¤NRUD8A7"3>UP pCR üK,/)quE"ÌJ CRT JÀÂWÔ5T¸¹?zK×ØE2BA!<6<"
"ASCOGI2013 ID"cStage noÕÓIÍ< FOLFOX6 F Capecitabine ëù CRT
WÑ§Üø=T¯Æj`fl7 Kimberly Perez RIQSì;U"3pÈ¿Fö¿&pCRü--)'7©;UA!FOLFOX KÎÓIÍ=TP!6CpÈ¿J¶ó;UAÈ»v
þîE2S"±¾J CRT Ix5DÈ»¾J FOLFOX W¯ÆIs×Üø=T:F
K"Áò÷{ÇJÚ6RûØE"àIæha\J3µ#EöF5RUT!
@:E"VUVUK"uêÕÓJÒEPàIæha\79"ÌJ­Ø¨þEKtÙr"±æFPüHÛ±¼uêÕÓWÍ·F<"QS!H¨þÄýF<D"tÙr¾WôØF<A mFOLFOX6(Bevacizumab&BV'IQTÈ»vþîW0]%a£"±æ¾WôØF<D"[fg_iWå<í«ÅË¡ù73F;UT.Gy J CRT W¯ÆIÑ§Üø=T­Ø¨þj`flJ"´ÏnÊ¤
S1 Wëù<A/*#
ekc]iWðïE°OD¡À<A!È»vþîF CRT JÑ§ÜøIQT!H¯Æ¨þ
K½|ØIPìK³H9"ðïEK°J"´¤E2T!àIædXha\ÕÓWÍ·
F<AK½|ØIP}ñE2S"ÌJ¨þîEK÷éÿHðªIºAHyä¿WP
AR=®úH"´¤F5D3T!&UMINID$****++./1'+('&#%$"!*)
æha\J3Ã²yä±¼ÕÓµ#WÍ·F<D"mFOLFOX6(Bevacizumab
IQT¯ÆvþîF"S1 ¯Æví«ÅþîWÑ§3"primary endpoint W pCR ü"
secondary endpoints WpÈ¿&ö~¥·æ"ëµæµ'"R0 Ã²ü"Éü"
Downstaging ü"-ãñæÁÌüF<èwW4!

< Y µ F L 8 R P

15"!%$#&
ø¿HÃ¿X--".K¶B!;LÿòHAF"«'e][L¨9ÁÑ§ôóXëÇHAF9V?H<>TWV<"ê÷KM"Ra$Rb K¹ªXABVôóàG"|ùwXA@C R0 ÙÃ$G8U"µFáL MRI"CT JIKSV

å.GL9C

W;X=DBÆIHöAF9V!
!Ôô7¥0£sÈODMç7Gy-£sÈLei`Üùw%N23"ìóºr? í3)&!.1.'.1/ei`ÜùwLHÅÁ

<þTWF9V%N23"ìóºr? í2)&!¹/ãQùwei`ÜK:=V Circumferential Resection Margin <ÚAF9V%åÈ-mm s!&!¼K<6sÏGL>NÎÀODML>s|KtðAL>~è»¾Lø}HJTJ9!éæODM1<KÎÀBV%Ïîú AI"ìóºr? í3)&!ôó<°:K1mm sÈÎÀBV
&!

%"#$

-&<Y/E0G/EÞ>xKSUâË÷Kôó%à&HÐï@WDÆI+àLöM"üà"Êà"õ2à"#{"z¬9HA"!2+¬9
QàJ4È,MÃBV!
.&MRI"CT XC9D¾áÐïKF´L9CW;X=DBHÅÁ <þTWF9VÆI!Ôô7¥0£sÈODMç7Gy-£sÈLei`Üùw%N23"ìóºr? í3)&!.1.'.1/ei`ÜùwLHÅÁ <þTWF9V%N23"ìóºr? í2)&!¹/ãQùwei`ÜK:=V Circumferential Resection Margin <ÚAF9V% åÈ-mm s!&!¼K<6sÏGL>NÎÀODML>s|KtðAL>~è»¾Lø}HJTJ9!éæODM1<KÎÀBV%Ïîú AI"ìóºr? í3)&!ôó<°:K1mm sÈÎÀBV
/&Ý0t< Ra ODM Rb G8VÆI
0&R0 ÙÃ<$G8VÆI
1&|ùwLJ9ÆI
2&Performance Status%ECOG&<,"-LÆI
3&áµFHAF6·ßF8"F8"cfdiF8JI<¯§@WF9J9ÆI
4&¹Dæ$%©Õ"Í"%"ÓJI&L$<½25³@WF9VÆI,,,$mm/;E)-.",,,$mm/j&Ö*0"/k¦ñÖ*.",,,$mmlÄ(Ö*-,,",,,$mm/mbd\hai*5#,g$dl
1
n GOT"GPT)ULN(.#oØäaefai)-#
1mg$dlpØ[gZ^_i)7%×É*uLÈ¢&q Ccr*2,ml$min$body
5&Ì²Ûº$G@­L¤ûB<$JÆI-,&±¡®KE9F¸;Ò;T3ÂKFýv<þTWF9VÆI16ÈUPVSQ´³pE­=L¡<6kµâFä®Z«z

/!

-'),

,(S1"Oxaliplatin"5FU"Leucovorin"Bevasizumab F6>M9F¸ÜxrBDLå-(¼DÚfÎFsbæF5Lå.(ÊE­<Õ©âFsbF5Lå+ [FÈÃOBJD7l§OÛ=Lå/(.3#0(¼D~Ó' Ïª"o¦ÇaØGÇ©_"RYTX%W¾DºÁÍ"£Ïª"nÏªDC(OÛ=Lå
1(lj¦F¢yhOÛ=Lå2(Æ·^OÛ=Lå"5L6Gä9KÆ·^:uNMLå
3(cà',¿/g[H@G¥ÝÔ(F5Lå
4(mçF@IE¨ :ËßB|8KMLw"Ñ¥F²áå
,+(»¦ÒpH@GÙÍto:0Ä[½F]¦ÒpOÛ=Lå,,(ÂFeÅ¦'\(F5L¦"ÂÐH@GÀÐ,-(vq×F5L±¦,.(?F¬"¯¹`:­B<AÏ¶¹BÉ°<@å"!'(%#$&
mFOLFOX6)Bevacizumab'Beva(0mg Ì¸Üã1R%SF{" LOHP ¸Ü9K
/Gy O}<"9K1*,+FoE/*15;A S1 ÓÞdkÕ©âÖ0+#O}7'¤-(!

mFOLFOX6)Bevacizumab'Beva(0mg Ì¸Üã1R%SF{" LOHP ¸Ü9K/*1
5;A S1 ÓÞdkÕ©âÖ0+#/Gy O}<"9K1*,+FoEO}7!
.!

0+*%#$&"(1"5FU'bolus$/++mg&m2("
mFOLFOX6)Beva G"i R % S Day1 E LOHP'30mg&m2("Bevacizumab'5mg&kg("Day1 9 K Day3 E 9 ; A 5FU'infusion$lLV'-++mg&m2(-/++mg&m2(F¸ÜO}7!,R%SO-o',/¿o(B<"1R%S}7!

: ^  Ü L 5 U R

17CL" LOHP ½Õ9W0)2s5=G S1%RT ]

AY!S1%RT M"S1 ]±ÅÎªK5\BG-k0,)2,mg ]-À.k"µÓKGy½ÕAY!S1 M".s½Õ
L"-svÑ@"CL.s½ÕAY!¢M"­ÝÇpÌM-k-#
3Gy"-À-k"
z.3k1,#
0Gy IAY!¢ÌMÛ°Ë8VNË9WL/Ð¢T@<M®8VNÛ°Ë
9WL0Ð¢IAY!-kLÜK86G/)0ÐAPG]¢AY!Ê­ÜM S1
LlI¿Kl@"¢M1k{ÖÀ9WxÖÀQH

6'2ÏLR{ÖÀ9W§ÖÀQHL/k("Ê­Üts´KÔ¹vtsM¬=J6!¢9W2)-,
LsK]

7>IIAY!

ÉioÜÌLÒÍKF6GMu¹@J6!
"!,143-50#+(&%
ªÔ¹£ß©I~ts]Å/KA!
0"

.,-.#
--

.,-0#.

.,-0#4,1-./$#%*(!+)'&

RB ¸j"~lLÔ¹£ß©$.0ß'~ts&.,-0#-.(
t² pCR Ø /1+"á³ pCR Ø -1+"α*,#-"β*,#."|Þ3,+*.-ßrLÆºn£ß]Ù@G.0ßI@Dª¶KGÔ¹£ß©]0/ßOÈ '~ts&.,-1#
2(
t² pCR Ø /1+"á³ pCR Ø -1+"α*,#,1"β*,#-"|Þ4,+*/4ßrLÆºn£ß]Ù@G0/ßI@D0/ß¼àqÚ

¾"ªÔ¹£ß©].0ßH¬¹@D!CLwI@G"ÜÌLt² pCR Ø]/1+"á
-"β*,#."|Þ3,+I@D¤".-ßÄ×IJY!
³ pCR Ø]-1+I@"α*,#©Lm£ß]Ù@G.0ßI@D!£ß¼àtsM¾h IRB ¡Á'.,-.Â--{(".,-0Â-.{
QHI@D!
@9@CL"£ßª:Ã¥K¶H5EDDS"VX6_baf`ecd]S?@".,-0Â.{K¬¹]È@"ªÔ¹£ß©]0/ßI@D!CLwI@G"ÜÌLt² pCR,1"β*,#-"|Þ4,+I@D¤"/4ßÄ×I
Ø]/1+"á³ pCR Ø]-1+I@"α*,#JY!

©Lm£ß]Ù@G0/ßI@D!>ZK\B"£ß¼àtsM.,-1Â2{QH

I@D!
·«tsM£ß¼àÚ/ÂsI@D!
)*$/2.'£ßªM¶K¦R".,-0Â4{L»H¯0/ßL¼à]Ú@D!.,-1Â0{>[K¯£ßLÜ]q¨AYÔ¹H5Y!EG">ZgK primary endpoint H5Y pCR Ø]
ÅH;Y}RH5Y!

»1mdqjg!þM÷B]ÞA5Î#ÆSNVÖùvïÂ¨

18

%

&

¢-JO"Ñé<ÉçS=NéMÑéS=`ìV¶_D]?KJäô|ÿ­`ÛÜDB]ÆSsiotYÂV[^I5]!dfqjJO"Capecitabine(Oxaliplatin MZ]S=K Capecitabine 7K<ÉçS=NýÅ&H«M TME `³6siotN PhasevÂ¨:³_^.'"pCR N,.*K;·@^I5]!UE Capecitabine(Oxaliplatin MZ]
S=K Capecitabine)Cetuximab 7K<ÉçS=NýÅ&H«M TME `³6~ÌNõ¿å)Â¨/'JO"b$nJ pCR N3*"++*J4\"FÃÚYI2wJ4FE!
Òß³!þM÷B]Ñé<ÉçS=O
yNâ¬MO­Ò»1Nâ¬MO­:µ5YNN"}%:A5?KOSTOÙ@^I5]:"Bosset [:;·AE EORTC ,,3,+Â¨ JO"CRT «N:ÓS=YäôQNH:ÙC@^L9FE!?N©{NzGK0'AI"ËÑ«M:ÓS=`àJ;ENO.-*@?KÕL5?K:>[^I5]!?NEX"Ñ«JOL<"Ñé CRT éN Upfront chemotherapy `²QBR;J4]K¥WH=
I5]!?NZ6M"ÑéS=`ìV¶_D]?KMZ\|B­`ê6æPOö'LY

NJ4\">§NxOµ5K²7]!
S1 O"5FU )JM<Éçñ¾K`FB]KKYM"5FU N6´ëJ4] dihydropyrimidine dehydrogenage&DPD'N í  ½ K A I TS1 M 0 ¶ @ ^ I 5 ] f o p h r&CDHP'MY<ÉçNñ¾K`FB]?K:Çº@^]¤® 5FU £E½J4]1'!S1
ü½K<ÉçS=`¦(AE;·O5<G94]:"Sadahiro [O"S1&,Í&H+ÍE,Í&H'(<Éç&./Gy'Nùu%vïÂ¨MI S1 NKU`"Ý&HUMÛ>IY
DLT :,X[^C"pCR NY,,*&0%,1'KT°J4FEK;·AI5]2'!ZFI"¸"¤® 5FU £±:a½J4\"<Éçñ¾K:4]K;·@^I5] S1 `<Éç×ÉK)Ä7KAE S1%RT S=` mFOLFOX6(Bevacizumab S=N«M³6siot`èûA
E!S1 O~8JO!þM÷B]VÖÂ¨KAIK5[^I8[C">§Neqilqk
c$Oµ5!
! $ # "
ÑéS=K<ÉçS=NýÅ&HMZ] pCR NN¯ÛMZ\"!þËÑM85
I¼øNúJ4]XDô"/+#ã.ô`Wòô#.ôËÑ:.KL]!
ÊNÑ« QOL `²7]ÛJ"?NZ6LÎ#ÆSMZ]ËÑNÐÔOø9ÏLJ4]!
@[M">§O5á§KAI"Ñéð"*Á4MZ] pCR NGóÂ¨`³FI5]!¸«"pCR :ËÑéMµNMGóJ;]Z6ML^P"¡NòôÆSKAI"Ë
Ñ`ØPB] Wait and see æPYèûÀNzGKL]!Z\µ5¹ÆãKZ\µ5 QOL OÎ
#ÆSN1$MZ\ROB]YNJ4\"Mî#LÆSÈªNEX"¸«N@[L]§:3LK²7]!

8 I h  B 5 E D

#

19

"

_[BJZH;T6>?9_[oxH;fM6>?9C<>(aLev

8IlVh_[e)BW]jB%Askt<r:C=!
$
,'py

!

Y"rRg"S"~#\nduc

XA=GOV

m}OV

i{#UP#75&3'#-1.*-13#-+,.#-'py

Y"rRg"S"~#KBucNXA=GhB|@xz

7F`>m}OVi{Bbw@QAW=G^#XBq#58&6'#.34*.40#-+,-#.'Konishi T, Watanabe T, Nagawa H, et al. Preoperative chemoradiation and extended
pelvic lymphadenectomy for rectal cancer : Two distinct principles. World J Gastrointest$40*,++#
Surg. -+,+ Apr 27 ; 2&4'/'Chau I, Brown G, Cunningham D, et al. Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic
Resonance ImagingDefined PoorRisk Rectal Cancer. J Clin Oncol. -++1 Feb 1 ; 24
&4'$113*2/#0'Dewdney A, Cunningham D, Tabernero J, et al. Multicenter Randomized Phase II Clinical
Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative RadiotherapyWith or Without Cetuximab Followed by Total Mesorectal Excision in Patients With$,1-+*2#HighRisk Rectal Cancer&EXPERTC'. J Clin Oncol. -+,- May 10 ; 30&14'
1'Bosset JF, Calais G, Mineur L, et al. Fluorouracilbased adjuvant chemotherapy after
preoperative chemoradiotherapy in rectal cancer : longterm results of the EORTC$,3/*4+#22921 randomised study. Lancet Oncol. -+,/ Feb ; 15&2'
2'Nakata E, Fukushima M, Takai Y, et al. S1, an oral fluoropyrimidine, enhances radiation
response of DLD1//FU human colon cancer xenografts resistant to 5FU. Oncol Rep.
-++1 Sep, 16&3'$/10*2,#/II Study of Preoperative Concurrent
3'Sadahiro S1, Suzuki T, Tanaka A, et al. Phase I/
Chemoradiotherapy with S1 for Locally Advanced, Resectable Rectal Adenocarcinoma.
Oncol -+,,; 81$.+1*,,#20#xyèÏ@;+9­ìù¿1AfRSi$T$Aó

8,-4.3%0$"#15729&*'(+!)!&/6
ÿ
<3

ð'

í¸º=*KqË­ìù¿1A¸,ÌÐBrÓF<ø-=É«?~Û/²4L<+K!­ìù¿1

A4I?K¸,ÌÐ¥ÇA9F@B"§?K¿1óÎ#qËä#¸,á¦ËA"G"°D=@î¿@©ML<+?+±È?Qho$_@HKÈ¸,üAó/ø{>¨,K!ï"Ê©kle$i"¢¿1%ôÄ¯ýò/O"Úß/Oç&"Õ¿1@-2KÈ#x,üó/ÊE"#xyèHJAQho$_@HKÈfRSi$T$C¸,÷âAó/Þ$4L<+K!
þBÂãêÚ>¬+/O[p]$/é=N©+"í¸Ëº=*KqË­ìù¿1@Ø5<"in_Tl$go$XRak$]$N)+9#xyèÏA¾ü@;0"­ìù¿1AóÎ#qËz#¸,á¦Ë@MK#xÝæ¯ýAëàN©+"8AhogPRmpV@;+9ÈfRSi$T$C¸,÷âAóN$µ6!

1/&;6þBí¸ËAqË­ìùî¿@Ø5<"÷Áâ@©ML<+Kz,KvNÏ6K3>N$â>5"z,ü/#xñ@(,üÒ£@·â@wN®½5"#xÝæ¯ýNÏ6K!Ý¼w×"-HC"®½{ñÆ/=B¿1×%¾À"Î×&N)+<#xyèÏN©+"­ìù¿1AóÎ#qËä#¸,á¦Ë@MK#xÝæ¯ýNéà
5"z,ü>A#x,üAú)A{ñËG'£C¸,¤}>06KfRSi$T$A

óNÊFK!þÌ}>5<í¸ËA­ìù¿1A¸,¡ûz%å(¼ÑÜ&G¸,ÌÐ¥Ç@Ú01ª6K3>/Ù6K!
1/&80
27:5>&+(),"*".'4=96%-#$!
í¸º=*KqË­ìù¿1A¸,ÌÐBrÓF<ø-=É«?~Û/²4L<+K!
( S$^$kRbs,N{ñ>6KÈ9?f­ìù¿1A4I?K¸,ÌÐ¥ÇA9F@B"!
) ¸,
RSi$T$Aó"?IC@È÷â¸,üA9FAÈ9?¸,]$W`aAó"!
á¦ËAkTdZj>Î!'£Nà6Ku´A"/ö*=*K!5.5?/I"­ìù¿1.tAÈ¸,@-+<B"Åz»¿1%GIST&@Ø6K_oYpUc$\Ô%
imatinib N³)59¸,NÃ+<"â?¸,Aó@B¶:<-I7"­ìù¿1.t@-2Kõ&â?¸,ÌÐ¥ÇA9F@B"È@HKÖâ?¸,óQho$_Bø{
'ÂãêÚ

s

ù

Í|

¹

6 W Ñ j G 0 O K

21

«B0S!
²ÆJBG¿=MÜnF48SF²÷¯£G'ëH"DNA"mRNA"ir_ÕGw
BGYf-F²÷6'ëF¯£;TA*GôV09A7?6"I^-EÑj·Na´úVb3SqY\y$]$NÑji$akmGFFHÌ@A1E1!>G?L"ºESÜnFõ#ó1#Ñj+¹óGVNÑjôøúG?LFH"ÀJBG?Ü¯£F¼UT

A1E1ÈìEXv$jFPSìÑjQGF6L«C»3S!
J?"?ÜH%ä&C<A"XE¯£6Á>Eé¥Nö]bfmG[#FPR?Ü$;F!=Sû]6Á>E²éV»3?è½F"²ÆJBFýBF;T?NÊK-Ñj]E
DG."FPSìÑjQGFH"½g-EPQB0RÞdEXv$jC»3S!
"ü­ÜnF48Sì
§B"í¼{}p$y"³¨Ün'HãÄRE6W"")6W3(
WjQF6íK"W4PRGXv$jFPSìqY\y$]$¢IÑjK-G
F6ýF41A(Z;TA1S!T¯£H>G²Æ(Z;TA1SW4GXv$j
V¿=MÜnF!<A¼1"ìÑjQGFVZË=!
3()1+0$&'/-$,"#!
W4G¯£HO¾F41Aù¼<A¯£6íLQTA4R"¾<¯£H´îVD<A1
S!:F¾<F41A{}p$y"³¨Ün'HãÄRE6W"")6W3("ü­ÜnF
48SìWjGFF41AH"W4÷HJïCE@A7A1S!J?"§B"¹
6WÅÑjVÝ8?×F41AW%2ÄRV÷<?¬"MG¹6WÅ'äk[n^c"azdis"fojou(HW©GMF¸J<1¦Vb3SÏ6VQ5FE@A1S+()-(!>G{]ogzC<A"+(òµó/ÄRN Myeloidderived suppressor cell
'MDSC(EDGWeòCV_=SÄRGðN57Veò=S",(¹6WÅFPRXx
m$dfV¡:<?ÜnÄRV¹±,ÒÄR6oê<Ün:-¹±V,Ò=S:CBÜn:-ÄRçó/ÄR6`8;TS":CED6»3QTA1S!,*+*B"¤6¯£×GS\
QH MSKCC"NY"USA FAØF BD ÖGÂìt$cYm{$i$'LSR  Fortessa(Vc1?W4GVæÄF&Ç=S;ÓGdflzGhFô¶<?.()+*(!²Æ">Gô
C<A MSKCC"NY"USA B¼UTA1SÛì6WWjQGmåFF41A"TW|oi~`Q6Û"måÎ°"Ñ°FKà-FÃc;TA1S!²Æ"@T¾<BH¤6¯£×GS\6,*+-BPR¾h6W¯£hi$FT÷ÚQGÙRATV²ÆÉ<A1S!
2/-%.*!
T¯£H²ÆÂM(Z;TA1SW4GÍ05Q¿=MÜnF!<A÷V¼1"qY\y$]$¢IÑjK-G&ÇV¼2ñâG¯£B0S!T¯£Há/7"'U±(C¾h6W¯£hi$'S\"ãl(6¤6B¯£V¼2!÷ÎiH²ÆJBFá/7"¢I¾h6W¯£hi$G¿=MÜnj$zC<A"¿=MÜnGÚß#­®ÿVc1Aþ
ð¯£V¼1þðGôV9A1S!>G²ÆJBF9;T?Îi¢I

veZ_mF

@AªÐ-F9;T?¿=MÜn®ÿVc1A¯£V¼2!ÚQHT¯£ÚQGF×B
0S¤6¯£×GS\G¯£Ô'¾h6W¯£hi$(F41A÷V¼2!

.}~ðÚGA1>©÷%½AHfXYj&Z&H

22

ý

7,+#*3"%$0&,Iø´×¶C0Ru×©÷%½AGä:B"jocZm&hp&^Xel&b&U
71>.}~ðÚH»*GA1>õµH¹.}Hè®_`dkU°7:ÚU¤1"=HiphWXnq\GA1>ÐfXYj&Z&J´="ëDFQ2R.}~ðþ~'
±Hòê$

ýU¤2!

,ØD:B©÷%½AG37R(´='2­3¡¹H5à(N5j&Z&H
òê"Ð´=*ýG@F4Q"ø´×H©÷%½AH´=ØÛH¢ÌG¥<R8D4æ

56å<R!
, + 5 6,+56#(8!
,Iu×©÷%ù½¹|UªÐHjocZm&hp&^Xel&b&U71B.}~ðÚU¤1"òyÉ@3OJÉ@öCH³ë)UÿÚ<R8DGOQ"Ð
55àj&Z&J2­ß¡×5àj&Z&H

ýU1ëD<R!òê9S>fXYj&Z&G@1BI"²ÜöJâ²ÜG31BHæ0ÊU¤1",öC=HfXYj&Z&H?Æ~7KHü×G@1BMÊU¤2!9PG"òê9S>fXYj&Z&Gï<
R'±U"ëD:>2­4GáH¼C°79SB1RÍ§GI"8H2­Uù½½A¬+
G37R2­ß¡¸U¤1"ù½UäËD<R?Æ~7HýU¤2!

'1#2/-)!
,HÅìóæH²Üö>;wzHÇûU¾7"ÚG!8F©ù½"u×÷%ù½
Jíx×©½AH¹|ãH«ºUÓL>!¨<4Vaqb&CM²Üö>;zHÒÙUÓLR!«º9S>u×©÷%ù½¹|U71"äËI´=ipe]&oGÂ?
>´='rÃÝ=*ô@"sÓ¤@Gä<R=*ôú@(4¤TSR©ù½É@J¦u×î÷%ù½É@HÚñU<R!
'1#2/4.!
¹|ã'-È+*),*ml(U71B"jocZm&hp&^Xel&b&U71B
Ú<R!ãëFÚäË&·I+#.}U£Ø<R¬+H¬+Õ%ç4:©Ô4:9Ö¬+'Myeloid Derived Suppressor Cell ; MDSC("Th1"Th2"
Th17"[m&/¬+"Ö×/¬+".¬+"NK ¬+"NKT ¬+"ç"¿Î¬+FE,#¬+HüNtÁéUþ{<R#/j&Z&%/¬+HCCR7"
CD45RA"
CD27"
PD1"CTLA4"
ICOS"
LAG3"
Tim3"PD1"
CTLA4"
ICOS"CCR4"NK ¬+H NKG2D"¿Î¬+H CD11c"CD123FE-#¯6ÞÏ40RÍ§"!8G~;B$;ÞÏ",U71>½A¬+NÀvÑÄnqgH.}ÞÏë®U¤2!

4 Q ¢ ' D / J G

23

2/03#1#!?SNK6M,IC",z¨ãì©-Ds}'ôª¿d$V$DÔ!
-z¨ãì©-DÿÿÍd$V$DÔ!
çcibRTgjWA*®ë%}^$[AI°8ËØCyÄ9N6A@·`TUd$V$F¢'[$X]_DÔP1!
@UHELM<,:B+'$("
ß×7O<øqrÝ,ïC>0?E"©-Éµâ@DçFPÔ9N<HC":O;OD±+CÐr8<Û§«ÏFafbRTjÏC25N!
,PCR ôCKN×("-øqÇ¶A"!
!
.©-¸¬øqrÝõPbi$YT_e$[$@yÄ9N!
TA4R.QK*%&J7P:B+'$("
øqrÝyÄDÀvA8?'ÿÿÍo(A8?ß×7O<øqrÝyÄvC>0?E"ÆâÖtÏDKN²Z]_P!0?Ñúç²P1!:D
4|å7O<øqrÝèrC>0?E"*®r!PûØA8<ÎÆâ²C?ý!¿ÆÑú²P7LC

0"üÊÂÿÍ#ÿÿÍd$V$A8?*®r!4uæ@/N3ÞP1!
O;8,<>-),F=D9*G5
ö

D­ÙàÑ}DÆâ)%lnxD¯åPª5<!&4Q

Zj[$C20?EÆâ)%nxD¹ÃPºH<!yÄÐ³@/Nä©"k¿ãìä©FÚm¿©-D~¥pÏD¦P0*®´óACÁéP=<!ß¡C§«ÏD|ñ%ÛÏ"afbSjò÷Ï&I=<!¦P=<~¥pÏCÐ8?z¨õêùî£"õâî£Cð5?dh\Vf$bi$YT_e$[$P!0?yÄP=<!yÄÐ³î£E"Ò
þ$D¼þ$#¾õ%MDSC&"gjaþ$D CD4 "¿gja"CD8 "¿gja"*õ"NK õ"NKT õ"¾¿+õ"¼þ$#¾õ%MDSC&C>0?yÄP=<!í½Dÿé¤A8?øqÓÜõDç{áCÀ8<%»)&!ß¡CöDÕÅ^$[A8<!

$#mMDSC!monocyte Myeloid Derived Suppressor Cell"in fresh PBMC of OsteosarcomaDÿ×A8?

wCÌM"k¿ãì©-DøqÓÜõDçcibRThD^$[DBNÕÅP1!:DÕÅ^$[P!0?")&z¨ãì©-¢'È"¢'D

WX

24

ZxBa=3;jqCPJKS%L%C[ef|CW~kCgRVQIJUC]Hi3\pjqCY^_rwS%
L%CmHi4!+'\pf|CW~kCgRVQIJU@bAhH]8"\pjq\pjqCh{S%L%CmHi4!,'7G;WX`

nB<3>D"9G:GCtB}X8;osf|CqzuB56FgcEdlC
mHWyv"QV%MJOT%N%?i4!
"!

*'Ghiringhelli F , Menard C , Puig PE , et al . Met ro nomic cyclo phos phamide regi men
selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector
functions in end stage cancer patients. Cancer immunology, immunotherapy : CII 2007 ;56$/-*(1#+'Soeda A, MoritaHoshi Y, Makiyama H, et al. Regular dose of gemcitabine induces anincrease in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced
pancreatic cancer. Japanese journal of clinical oncology 2009 ; 39$020(1)/#,'van Cruijsen H, van der Veldt AA, Vroling L, et al. Sunitinibinduced myeloid lineage
redistribution in renal cell cancer patients : CD1c+ dendritic cell frequency predicts
progressionfree survival. Clin Cancer Res 2008 ; 14$.11-(2+#-'Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, Rasalan T, Adamow
M, Yuan J, Wong P, AltanBonnet G, Wolchok JD, Lesokhin AM. Computational algorithmdriven evaluation of monocytic myeloidderived suppressor cell frequency forprediction of clinical outcomes. Cancer Immunol Res. 2014 2&8'
$1*+(+*#.'Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA,
Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, Merghoub T, JureKunkel M, Wolchok
JD. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF
inhibitor. Cancer Immunol Res. 2014 2&1'
$0)(2#/'Postow MA, Yuan J, Kitano S, Lesokhin AM, Wolchok JD. Markers for anticytotoxic
Tlymphocyte antigen 4 &CTLA4' therapy in melanoma. Methods MolBiol. 2014 ;1102$1,(2.#0'Kitano S, Tsuji T, Liu C, HirschhornCymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S,
Yuan JD, Wolchok JD. Enhancement of tumorreactive cytotoxic CD4+ T cell responses
after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res.
2013 1&4'$+,.(--#
1'Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T,
Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S,
Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of
the abscopal effect in a patient with melanoma. N Engl J Med. 2012 366&10'$2+.(,*#
2'Lesokhin AM, Hohl TM, Kitano S, Cortez C, HirschhornCymerman D, Avogadri F,

. 2 3 4 / - 1 0

25

Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Monocytic
CCR2#+$myeloidderived suppressor cells promote immune escape by limiting activated CD8 Tcell infiltration into the tumor microenvironment. Cancer Res. 2012 72#4$",+*%,*!
'&$HirschhornCymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM,
AvogadriConnors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD. Inductionof tumoricidal function in CD4+ T cells is associated with concomitant memory andterminally differentiated phenotype. J Exp Med. 2012 209#11$"('')%(*!

26

KRAS é³#Íä#æäEÛ;P Cetuximab ø*1ûFß{Õ´

KRAS :TEZL>.H[MIXV,KC!DW.?R!SR<P(2&GH]+'*. Cetuximab#q2w$%mFOLFOX6 1)/
Cetuximab#q2w$%mFOLFIRI ]Y.^JQ9NFA=0
H]B;3\O(27458"6".@U
ª
&%

Æ(

ä#æäE31@"qW[yVxWT*1=",çé³ó¡EMO"¦®¹Ë3MH'¢F'×T;PjWXq%Y%Tà°;P5§SQ@1P!$G",çé³ó¡EMOÞäF\nbWo÷3T§2T§>@6=!<F"ÞäGÞ67+?F+ÓEM>@-?F\nbWoE÷3
9QP8B5·9Q=!8QN-?F\nbWoA¦ EGFR ¦Ú$"WvifYzp%_x^tz"XZ\vouczp%_x^tzF&£Ë5DPòË5·¬9Q=!ý2Á´

AG"¾

1û5ö"öÜ

(BD>=¶%ÐÀöòDÈ§#­óFä#æäEÛ;P+µ¶1B:@F cetuximab&q2w'3MH
mFOLFOX6 J=G mFOLFIRI ø*1ûFþÖ|ÍØTì;P!ýF"ä#æäF\nbWo÷3FjWXq%Y%B:@F2Áç&*Ë5Ã9Q"ä#æäF¶1FÈúE¨A6P8BT
Ý:=1!

# ! $ "*//)ñ}©E§SQ=Þ!2Á´F"ä#æäF

1ûE31@G"md

lvr^z¦|Ë¸6$Tp%_B:"²WvifYz"J=GXZ\vouczFø*1û&FOLFIRI 1û"FOLFOX 1ûë'5ô½¶1x^tzB:@0:=!J=ñ"÷
³ôç¶1$B:@"¦ VEGF ¦Ú$A0Ppj]`qn"¦ EGFR ¦Ú$FaeZ]qn"
khesqn52Áíð9Q=!¡¯AG"WvifYzx^tz"XZ\vouczx^tzE¦ VEGF ¦Ú$L:7G¦ EGFR ¦Ú$Tø*;P8BA¶1ÌÏ5¤Ä;P8B5·
9Q"ô½¶1B:@¥7*1NQ@1P*'!
ÞäAGqW[yVxWT*1=",çé³ó¡EMO"¦®¹Ë3MH'¢
F'×T;PjWXq%Y%Tà°;P5§SQ@1P!9NE}ÒAGÎ5«îA0>="FFPE \zow4Nã¼:= RNA T*1@qW[yVxWT§2",çé³ó¡ÎLòED>=+'!FFPE \zowG"ÊâIBUCF1E31@"õ/ÔÅçÇáF=KEùØ9Q@3O"ÙÉFÂ4Få±g%bT¢R¤6E(~Eº»;P8B
5¼-P.è50P!ïAG",çé³ó¡ÎEMO"é³ó¡kb%z4N luminal
A"luminal B"HER2 enrich"basal like"normal like F.?F\nbWoE÷39QP8B
5·9Q"FÙ)ËTé³ó¡xpw4NÿEÑÿ:=,'!8F\nbWo5ïF2(êüÞ5¿ 2Á¸6÷#6 W ª / G 0 P L

27¶ô-Ë¼ãéàO1¶ÐD08×v<":G?M"ëGú¤ÅùãïG-}6Ú7
8Àü<?!ëDç)FÚáNÕ)E¬V&=T°ÝC0TD3RUT!uä¤ð}ÆFQSÚáGÕ)ÃVÈ!C7UI"ÚáF×=T-}6¾KS"QS01ª/GÉÛ"ðFAE6TNGDÙ;UT!
40þ1¶§CH"´~w/ý6õv"õØ(DE@?ª%ÇµõîEÀ#¡ðGá#âáF×=T+©ª/D<BG cetuximab'q2w(4QJ mFOLFOX6 K?H mFOLFIRI û*/ýGÿÑqÅÓVæ=T!
!®+óx#$ÿÑqÅÓ'Progression free survival$PFS(!ø©ãóx#$Ì."&¨¹GðÅD±êå;RF"þ§F£y=T­V×¹F">Gô-òþË¼F49TfYZj&[&Dþ§FQSèRU?'4QJw/ýG1¶ã{DGÏÃVóx<"",ãuä¤ð}ÆFQT_gbYhú2FQ@B cetuximab G&ÃV'Òzî5FA1B¸=T:DV#ãD=T!K?"½fYZj&[&GðV2!
' $% ( " &" / ,#!350)1-2+*.
:UKC|%H",ãuä¤ðFQSá#âáG_gbYhú2V2V@B
7?!+))-í5R+)*)íKCFÇµõîÀ¡ðÚáG¿ÞC6W¢ª/V¦<?·3
C"ðÎ6Çµ;U">G FFPE Ë¼6ì¯zîC0@?*))3V×¹D<?!á#âáG¯³ÖG FFPE Ë¼QS RNA Vß²<"jY]oXnYV*1?",ãðuä¤}ÆV@?!¥E<Íw]labmp^ýV@?{"á#âáHÚ78,AG_
gbYhFú2;UT:D6«;U?'Á*.(!K?®ÄúúÆV@?{"+AG+Ê
FQ@B,AG_gbYh6X&c»Fú÷=T:D6«;U?'Á*/(!:UR,AG_gbYhCYmed[pi&an`kpN<8HZ\_mhlcpi&an`kpD EGFRÖ$G&Ã6tETzîÃ6«;U?'Á+(!ÖãFH"Ymed[pi&an`

kpDZ\_mhlcpi&aG*©ª/G PFS F41B"Cluster B2 HÔG Cluster QS
NÜ1V«<"éF Cluster A1 QSH&sFÜ5@?'Á+.(!K? EGFR Ö$G PFS F41B"Cluster B1 4QJ B2 H Cluster A1 4QJ B2 Dñ<BÜ1V«<"
éF Cluster B2 H Cluster A2 QSN&sFÜ5@?'Á+/(!
rºG{QS"þ1¶§GöÂD<B"jY]oXnYV*1?",ãuä¤ð}ÆFQ@B"_gbYhú2V1"þ1¶§ª/G{"'DG4ÃGæV2:DD<?!

28

KRAS '4,7.)*2!32(#0"% Cetuximab 5896$1&/-+t)t)]kg_w:?BJWNO%

,#bl93`y^JWNO%_w!)((;e}$~}a<]kgT[SDFY:?57+6;JWNO%:2C4!
-#ouw!)((;e}$~}a< component 1.?=*8du2CBr:E%Ps: 3"component 1 ;;h/@,*",)"-)"-*;q: 34!
t*t*

JWNO%:?Bvzcx,#)mn:.1B"FXRQH\U%N>30<GILXTWP\U%NZMV\; PFS&'!P |<[KW\Jf:?Ajp!
-#i EGFR i{; PFS&'!P |<[KW\Jf:?Ajp!

8 [  Ü K 3 S P

29#!04"54.-:*629),
³#´³

J74ELÓ-)(KÆºF KRAS v¹K¥Êu8<XW!?K5

CÓ2)(8`gq*+7TN*,J¾QUXW8"`gq/*IH¬KÈtJRµÆºJ¾QUXW!
EGFR KyÛJt²>W KRAS v¹J¥ÊuZÕ>W¢ßL EGFR ®8ÏF3W;G8<X" EGFR ®Kh\]k%^%G=EwÂÞ¡FRØ<XE4W-'!BRAF
v¹ÊuL KRAS v¹ÊuG»×J EGFR ®ÔKh\]k%^%G=E¯<XA
8"cetuximab KÜ~8<XW~8¼UXE4W.'!wÌF BRAF v¹ÊuZÕ>W¢ßLÒ§K¢ßGÃ=EÖ8QEÇÝF3W-';G8<XE4W!PIK3CA v¹ÊuL"KRAS v¹Ò§ßK¨F" EGFR ®K~Ö«xF3WGË<
XE4W/'!s£TV"ÎJ74E;XUKv¹G?Ká½K¬Kàv¹&NRAS "AKT ¬'h\]k%^%Z¨J|6W;GG=A!
*'KRAS+'BRAF,'PIK3CA-'NRAS.'AKT/'?K¬"¨}ÀIàv¹
$!CpG 8(&%'+71/,3
³#´³

JL DNA K CpG ÈtFldoz8;W CIMP&CpG

islandmethylator

phenotype$CpG ÈtldozÄ'Z>RK83W;G8±UXE4W!¸ªI CIMP
Kk%^%ÈtLOBâK­4G;YF3W8"KG;Y CACNA1G "IGF2"NEUROG
1"RUNX3"7TN SOCS1 K.ÈtKldozZ¨>WK8wÂ·F3W0'!<UJ";K.v¹K¬J"MLH1 v¹Kipm%c%ldoz¨Lk\_paen\fÇr¶¥G
à>WAQJÙF3W!¿"CIMP Ú¥K°³

L5-FU Zj%bG>WzÜÍKÕØ¥8µ4;G8<X"ÔÉÜÍGKà8¨<XDD3W !¤Á°³1':WÔÉÜÍG CIMP Kà¥LË8I9"ÎJ74EL¤#Á°³

J7

K CIMPZ¨="?X@XKFKzÜÍKÜ¦©ZÃ>W;GJTVà¥K¨ZÐ>W;GZÑ·KMGDG=A!
*'CACNA1G+'IGF2,'NEUROG1-'RUNX3.'SOCS1/'MLH10'?K¬ CIMP KÅ{JÕØIv¹30

KRAS wâ¡$ÆÛ$ÜÛHÔ@Q Cetuximab ÷+/üI×qÐ¤"!DNA ,&+)(07'-*%/$8.5243%-1+IîÅÖÛH86DgUXnY^jU`órÝÅ'MSI(:ëLORQ=F:Ú
ORD6Q!MSI S§@ÖÛJ5-FU e%ZI²ù¶|/üHNQik]`:ëLOR
G6=F:m`nZfX^TcGÇ9Oú>RD8P"&õ/üI®ÅFIÐ:§
>RD6Q4(!=IAL"s{IhZg]\¯ô[obX©I"yÎ¿ÊÀS8=G6"¦/
~FIÐÅSå@Q=FF?A!
-(MLH1.(MSH2/(PMS20(MSH6#!PTEN '-*%/$8.5243
,Äwâ¡ PTEN IáªõE5Q PTEN [obXJ PIP3 SØko|@Q=FHNPPI3K &Akt 2IÅS,Ä@Qæ;S¥C!PTEN Iî¹¨J PI3K &Akt 2IÅ|Sx;=?"KRAS øu:G6¾EM EGFR 2IÅ|Sx;=@!PTEN Iî¹¨
HNP" EGFR ÓHÞÅGQ=F:ú>RD6Q-,(!=IAL"PTEN [obXIîI(!S"yÎ¿ÊÀEå@Q=FF?A!
s½IÇSäàH7=FHNP"ÖÛHÔ@Q&õ/üI¦/~S)Ò@QaU
Vg%W%Sî@Q=FS#¢@!
61´|/ü:óz"óÕ*FGBA¦'È·óíGÂ$îIÛ$ÜÛEñ-I³SÿA?A»0SÔ¼F?A!
&!

%"#$

-(ýÃNPöµEIçt:èORD6Q»0.(ò-Î¿àHÛ5Q6JÜÛE5Q=F: ë>R"Î¿àHÖÛîIÌE
5Q»0/(ÖÛîÏI­²ÓM?<JÆÓSß±E;Q0(îÏKAJávÏÎ¿H86D KRAS $Æ: ë>RD6Q
1(çt¬èêIì1:.,s½I»02(ECOG performance status'PS(:,).E5Q»0-ïÝ³(:Ñ½E ë>RD63(¸G<FM-CIÒÝ}íGðàòø'RECIST ver-#Q»0ã3Í/,êséI_%[HNP"s{I³SÿA@òøS-Cs½(?D6Q=FF@QÍ¦/Hû«Ë¦/S£?D6Q»0J"û«Ëº«°.HÁAH±?Aðàòø"KAJû«Ëº«$IðàòøS(@Q»0F@Q
p CT E.,mm* þJdkWl CT E-,mm*"Ù-1mm s½IkobÉòø

@ \ ¤ í P ; U S

31

x âÄÌ@×NÜß
4).£¤íMFK_adsnrgvo&eRIQ^slh`vo&eP¤í@¡EZ"HZ
WP¤íOÝ·RIQÐêÔONJI®ï*N>"ªà« íãOFKQ¨ì.4-Õ~ÓOØ[ÖFN?JI°OQ¿¤íMFN<+
5)¿¤í¨ì?WÏð¢ÎRLO~O¥Gå¤í[éGYDM#w á¦¾íã 1©x Â¼¬[Ù=§ªíã(²ñçÃ½ª[¬B) /©yíã(Þ ÛÍ¤íè[T) /©z ptqvíã"æíã /©{ d^j`^v"698º /©| ÇP¤è 1©.-)ÏðÕVX3-Õ~¯P¹Æ@ÉEZY®ï..)Ïð¿.2Õ~ÓPi&fOVX"~Pµ$$³×[éGY®ï.2--'mm0~¯w Ë¶%
4#-g 'd7~¯
x ±Àî%.-#-,.-1'mm0~¯y ­Ú¶%/#-mg 'dL ~z ¸Ámstmv%{ ¸ AST(GOT)$¸ ALT(GPT)%.--U' L ~.#
2-mg 'dl ~| ¸bu]gkv%!

".c&eQ/©MF cetuximab Q"Day1 O2--mg':/[/¢?CK»äÓÐêF"HP©ÐêMFK2--mg'm/[/¢?CK»äÓÐêGY!mFOLFOX6 íãRIQ
mFOLFIRI íãQ"cetuximab OAÅAÐêGYDMMF"cetuximab MÑÕO©ÐêãLÐêGY!ÜÊP}RIQÈë·På<Ò·@ØGYRL"Ðê[ÅGYDM@L

AY(´0)!

&"$#!%KRAS }é´%Ïã$åãPÝD[ Cetuximab ú-4ýQàw×¸

32* + ) &
ðçô0ïýÍ$ìþ6Æ¾:Q²
XZê9^³C"-+,/ñ,,

·Ò"..·ÒM¼·CL6[!-+,-ñ1®"/08Qê9:5[!
(%

ÿ6Æ¸R"Ä4ý:ö"öÞ+NOIGº)ÑÅöòOÌ§$¬óQã$åãPÝD[-¹º4NCLQ cetuximab(q2w)8XS mFOLFOX6 TGR mFOLFIRI ú4ýQ"ØxÏÚ^îD[à!×6Æ¸M5[!@\TMQQ"#/è}é
´ó

ÐPXIL"ã$åã:/JQeni`oPù7B\"õÃº4ufsvQº4£:|O[@N:»«B\G!C9CO:Y"@QÓ§R5=TMW¡]¥;Q±M5Z"amjvguptR©6WQMRO6!F@M"ÿ6Æ¸R"-¹º4NCLQ
cetuximab(q2w)8XS mFOLFOX6 TGR mFOLFIRI ú-4ýQº4£8XSyÕÎ^îD[NNWP"Ó§Q^ÇD[GVQ6Æ¸NCL3zB\G!¦ EGFR
¦Ü(Ql`bq'c'NCLR"ÔÂQæZ÷Q£*Ù~´NCLQ RAS }é´û|Q
UM5[!RAS }é´%ÏQã$åãP8>[¦ EGFR ¦Ü(QÖ£2R'.P<E"l`bq'c'NCLRöÀùM5[!&R#/è}é´óÐPX[eni`où7N67ÉC6ÑZ¤MÉl`bq'c'^3D[@N^$µCL6[!TG"#/è}é´óÐQUOYE"ã$åãQÁ.Oó:_sckhrM5["CIMP"MSI Q

l`bq'c'NCLQ&^îD[NNWP"F\Y^íªÐD[@NPXIL"ã$åãQÉeni`où7NFQù´Ïøè{!K>^§7@N^$õNCL^§I
L6[!
! $ # "
ÿ6Æ¸Nl`bq'c'á°PXIL"ã$åãQù´Ïøè1:ÊT[
NNWP"eni`où7PX[ÉõÃº4gd'rQ3PXILº4QÌüP¨M;[NO[X7ë5CG6!
­¡P"ÿPA1^6GH;"ÛßOA¶^ä;TCG¢¯âýÍ:_¿èº4¯âQ,PÊ½ËCÈ?TD!
,',)National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. 2014#-)Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues andoutcome in hepatocellular carcinoma. N.Engl.J.Med. 359%,440*-++/"-++3#.)Sorlie T, Perou CM, Tibshirani R, et al.Gene expressionpatterns of breastcarcinomasdis-++,#
tinguish tumor subclasseswithclinicalimplications. ProcNatlAcadSci USA 98%,+314*2/"

2 6 7 8 3 1 5 433+%Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic review : Antiepidermalgrowth
factor receptor treatment effect modificationby KRAS mutations in advancedcolorectalcancer. Ann Intern Med. 154#*.&+0!)'((",%C. Kohne, P. Rougier, C. Stroh, et al. Cetuximabwithchemotherapy$CT%as firstline
treatment formetastaticcolorectalcancer$mCRC%: A metaanalysis of the CRYSTAL
and OPUS studies accordingto KRAS and BRAF mutation status. ASCO GI cancers
symposium. 2010 abst#406"-%SartoreBianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectalcancer
are associatedwithclinicalresistanceto EGFRtargetedmonoclonalantibodies. Cancer Res.
69#(/,(&.!)''0".%Weisenberger DJ, Siegmund KD, Campan M, et al. : CpGislandmethylatorphenotypeunderliessporadicmicrosatelliteinstabilityand is tightlyassociatedwith BRAF mutation incolorectalcancer. Nat Genet. 38#./.&0*!)''-"/%Jover R, Nguyen TP, PerezCarbonell L, et al. : 5Fluorouracil adjuvantchemotherapydosenotincrease survival in patientswithCpGislandmethylatorphenotypecolorectalcancer.
Gastroenterology. 140#((.+&/(!)'(("
0%Ribic CM, Sargent DJ, Moore MJ, et al : Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N
Engl J Med. 349#)+.&,.!)''*"('%Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab
efficacy in metastatic colorectal cancer patients. Br. J. Cancer. 97#((*0&+,!)''."

KIF20A I¥·>[ RNA ¥·*AÎW`rpikzdi{Mäj7`ÊdPM]34

KIF20A #12"& RNA 126748:,+)*-().$50<!'3;%$/9'<&%

j7`78^UGY®HeH1[«¤)N"7`¿NMåÖ#3>7¶9"»Êð×7µ^\CI=GVÕ®M½Bb7¶2;IH1[!=C7EG"j7`MåÖ#3³MQ_µ2"BM§¡ì_ä÷TL]>[;I7j7`MY®ôLNÔ_H1[!È&7}óL¸=Cj7`;1Ñi²« KIF20A+(
N"j7`¿NMúàL^[MSHNK9"åÖ#3LVZ>[;I_Ë>+¨_:C,(!>K^D"KIF
20A NÐ$M RNA ¥·*AÎ_T RNA kc_¿NåÖ#3LEèMJ~H1[ Lamellipodium'^ß
ü(RHUù>[;ILXZ"7`¿N_åÖ#3<@G2C!È&N"+FM KIF20A ¥·£ RNA ¥·*AÎL,S="njj7`öá_]2CRöáòâ_µEC¥";M RNA ¥·*AÎN"íÞjûI
íÞÔ_û'?#@#ãû#û#çû#ºé(L52GB¬_QI`J=U?"j7`öáMj7`¿N
L52G¶B¬=G2C!ä÷TPMapy%iMFI=G"KIF20A ¥·£ RNA ¥·*AÎ7 KIF20A
8\Lj7`;1Ñi²«H1[>ë_´4"RNA ¥·*AÎ_F1I=Crpikzdi{dMMB
L±:Cjv{fx%eulw§¡_µEG2[!P§¡L52G"KIF20A ¥·£ RNA ¥·*AÎW`M.¼rpikïÀMgÙ§¡L±:CF1KÅM!5ë¦75XO.¼rpikMR1¦7_µEG2[!

# ! $ "
7`rpikzdi{ïÀNÓ`M²7`ÀMX3KÃ¿N£MTÀINKZ"rpik
Ì"LNTaÂ]7K9"rpik7ë>[cv% T ¿N_>[R³LXZ²Ñ
i°_B>[!¾¢"j7`_#ÜL=Crpikzdi{dMMgÙÉª7µ^\"ØêhHNgÙ1LQY6KÊd°_=U[Ý·V1EC7"pvgs#Úv{ht%!ø
gÙÉªL52GõîþMVK._&ì>[;INH8G2K2!KA°2CM6"
RCÿ9MÛhHNKA°6K2M6õ9K6EG2K2!¬Á"¹<HB<\G2[7`zdi{M$JK_ñU[)¼rpikzdi{N"cv% T ¿N=Íboj%pLø5>[0&+*ÄM)¼·ìrpik_zdi{²«I=G5Z"qwm% T ¿NNë=K
2!¾¢ÏÇ<\Cj7`_#ÜL=C KIF20A ²«rpikzdi{dMMgÙÉªL5
2GV)¼rpikzdi{7]2Y\G2[-(!)¼rpikzdi{HN"X9<\[²7`RMfWÎ7HÒKHÊd°7O=9.("DR¿N6LX[H2ðK²«/Ë7;Z:[CUL"7`L#>[R[_X9=G=R3©ëVÆ0<\G2[/(!(7`­"Mî"CLX[I;]V1[7"4Z<\C)¼rpik7"ÿ9M7`ÛhL#=G²Ñi°_BH8K2>ëV´4Y\[!;\L#=G".¼rpikzdi{M7´|<\-S<\G2[/(!.¼rpikzdi{N"cv% T ¿NIqwm% T ¿N7=Í
)¶+$JIýG¯dædJ

8 ] Ð ^ J 2 U P

35>Yywmq=b\¡QV4Ioga<ZB+)&-)Ç£J(3ywmqE2X"e~%1Ã
MFxt% T ÃM\3ÏÈ±=D_ÒH8]P0\T4E9Y.(!OB";J(<Jywmq8e~% T ÃMFxt% T ÃMI*Ñ<ZYBRIK"ÖàÃMTzfv^%i
HGJ»¶*ÑÃMJ

V8EçE2X"AJùÃMHGIVYG,ñH»¶*ÑFP

W\CE9Y !(ÁywmqfmLK!ÁywmqfmFKý9:HY(Ú\/(R="½3`ÛR¹ê\?¤>YF¥û<ZY!ÍÿK KIF20A ²¾® RNA ²¾">ÒS]J!ÁywmqîÄ\å¼d8]ÔI/V="óêFR¹ê\³1>YËÕ4þ0õ`
ÛÎµ\¼4U)E2CB!=7="Â¬¼[ZBct|mqF OCVC01 S]J!Áy
wmqîÄ\Y3Bþ!õ`ÛÎµI63D"FSIóíø¥JRH(\ÿë>Y;F
KE9D3H3·à\2O5"!ÁywmqEKH:(Áywmq\Y3BP+8`ÛÎµ\ÓÌ>YE[82YF@$=B!KIF20A ²¾® RNA ²¾">ÒS]J(Áywmq
îÄJóêFR¹ê\³1>YF3ÏIQ\+IÊï\¼3"HA¹3BJ7"OBHA¹7H7CBJ7\'LYU)E2Y!N´¨I63D"KIF20A ²¾® RNA ²¾">ÒS
]J(ÁywmqîÄ8d8]Ð^IFCD,ñH¯üE2Y7\ï>Yp~j%h}r´¨\É>Y!
&'!#"%$*#KIF20A ²¾® RNA ²¾">Ò8d8]\úÝF=Bywmqfm^LJF+F=
D,ñ7\³1*)aJupd8]ôá\Y3DPôáòâ\¼CB²"KIF20A ²¾® RNA ²¾">ÒKìßØ[ö¢';$<$ãö$ö$æö$¿é(FìßdöEKMF]G?·\9R?"*)aJd8]óÜaE½?·=D3B'è*(!KIF20A ²¾® RNA ²¾">Ò\d8]ÃM7Wsnflb>YF"ÃM¯ü8ZÃMX7WÞBÃMXIJ
>Y'è+(!KIF20A ²¾® RNA ²¾">ÒK"in vitro I63Dd8]ÃM\äÙ$-<@D3Y;F\OW7I=B'D¸o%k(!In vivo ÓµI63D"KIF20A ²¾® RNA ²¾">ÒK"d8]ÃMJ<$-\cå<@D3B'D¸o%k(!KIF
20A F KIF20A ²¾® RNA ²¾">ÒK"d8]ÃMJ Lamellipodium I×ð='è
,("Lamellipodium J_fmv`~{pØ¾\÷å>Y;FIVX"d8]ÃMJ
äÙ$-I[CD3B'D¸o%k(!d8]KG«H8]ÃM×#E2X"G«HÃM

×#K8]ÃM"Z°ÃM¯Ò\5=ÒIäÙ>YÃM"d%pv^i%\¦;>ÃMF=D%WZY!;ZWJÃM
·\Ñ="×#JPI?·>Y.ÊÆHK

+IHX5Y!;ZWJ

×#K"K×#FKHY.Ê?

×#6+»¶IÊF=DP^LJF

×#ÃMK"d8]ôá7IÀÅ=D3Y!KIF20A ²¾® RNA²¾">ÒK"äÙ=D3Yd8]ÃMJ Lamellipodium I6&+H×ð\Ñ="Lamellipodium 7J_fmØ¾\÷å>Y;FIVXÃM¯üISª\§N>!=B8C
D"KIF20A ²¾® RNA ²¾">ÒK Lamellipodium 8¯ë<ZBäÙ$-­ºJ©
3d8]ÃM

×#J6+»¶IÊJ:ê82X"KIF20A ²¾® RNA ²¾">Ò

36

KIF20A '>A&. RNA >AIMCQT54236127)E=V$0BU+)9R/OJ'&.54236127UP*V$0)FD"K8/SG&.%'(,-?;/N<&.:LH$@#!

Z$ KIF%#A NRL RNA NRbeT4hm^XHcfOG\
KIF%#A NRL RNA NRbeT5!YPo*=^X4o*=Sj3('0QfO,0(:![Wo`1[WJ_3(+;fO<d72)/.

Z% KIF%#A NRL RNA NRbeT1o*=SjMa
KIF%#A NRL RNA NRbeT<o*=SjI S2-013)9CB@A>E-;1!SjMa*KlSjk)9
VgSjk3iF-;

Z& KIF%#A NRL RNA NRbeT4 Lamellipodium 64U]
KIF%#A 1 KIF%#A NRL RNA NRbe T 5!RNA p n D " ? " G3BP 1 1 8 3 o * = S j I S2-0134
Lamellipodium 3U]-;

3 R ¤ ç C . K H

37+#KIF20A  RNA ÀÕ§àåÃØjh_dC·¾jh_dD"Ä¶Æ¥ÛC HLA Ym]!¯BÆ¥7PO3"Ãjh_dDÆ¥ÛB«NGP>ho^`\qZ7P"HLA Ym]!@Ym]"¯BÆ¥
7PO!<C|"CD4'T ÛCinf$ä? CD8'T ÛD³z cytotoxic T lymphocyte%CTL&@AO!KIF20A  RNA ÀÕ§CVgc$hjh_dCSle
ÔëQxÃ9"Û? MHC Ym]!ÙEÄ¶:O6@Q×{ÓB9=+)(,Sle2MAOÃjh_dQb[Tq9=%±,&!æ¿C-(*-SleÇÉQt
Í7;A3M N-Ü¿2M C-Ü¿E@ KIF20A  RNA ÀÕ§CÀÕ¸ÃQ
Ú0L0B·9=C?"6CÃjh_dCh$nD"Xm$ T Û@inf$ T Ûæ©3Ò¦:OVgc$hjh_dQR?/O!¨¢ÁC in vitro ?Cì3R
ÛB»:OÛ®³¨BLN"Ãjh_dh$nCÁ2MÛ®³C.O
KIF20A  RNA ÀÕ§àåCÃjh_dQÎÅ:O!Û®³QÒI=Ãjh_dCHQWYanz9>"ê¬£Bä/O6@C?4O RNA ÀÕ§àåCÃØjh_dQ´:O6@3?4O!Ñ³£@9>kU]B»:OvÅéC
½}ÊãBLO³Ñ³£BLNºÑ³QÂFO!

P% KIF$#A HIF RNA HIUXN\^VKYIB@;=3RG:C" T LZ0AD>" T LZ_O3WM)5 KIF$#A HIF RNA HIUXNSV\^3TK9?<"@B@;=8.1'I7*/VKB@;=8IQ(!+6,63IQVKB@;=8JI(-438[E2]&50

3

KIF20A .1- RNA .1795:<$82*)'(%;"#*)'(+&',=64/!
Ãjh_dpY_qC³ÓÒQ¨¢9="ê¬yäQÞ¡89=ê¬£Q~:O!
ê¬£@9>"KIF20A  RNA ÀÕ§àåCÃØjh_dµQ°ì3R©BÊã9"r¸³@ß³QÌ:OuªÏ¼!¹ê¬£Q0âÅ?.O!<9>"Ø²CÃjh_d2M´O KIF20A  RNA ÀÕ§àåCÃØjh_dQÊã
7P=ì3R©B15OÐsÈÝwÖyC­AÌQ/"ÃØjh_dµ3

Xm$ T Û@inf$ T ÛQ@JB9>è§A3RÝwyËQáÏ?4>/O2Q

KIF20A D

38¯>P RNA¯ð&ÂCKpncgxYcyHÔU7S¿NJH I

Û>P!®óë~/.æ,H¿¥Ó²{HÎ$R"@Ý<2ÌRI2B"Ä;Ö6N2ÌGMPÿ|R"B6NÐQûRR¬3!T`tkyf'IFA(D±S<@ RNA¯ð&ÂCK÷³1¯pncgÚ¶'+#*mg&mL(R*#
/"+#
*",#
*mL&body HGOñ/
QR\q%fD>P½ßûR7ÁH*éÑIOáå¼¥D<BÃº>PEøC1P'¯+/ÐQ(!ýF78I"É+".ÉýFR+\%aD<".6¡ýFRO4>!ÅJWy
grVyfIzâØC1O"0¾WygrVyfI=("ªÇT¨H¢þC1P!Ùç

ôò'MST(RK"®óë~/.æ,Hoaf^r%dUm[TÕ¬U7S
ÐQH MST D)>P!B½ÑH'§-üGA2BIZw%gR«M<B·Ê>PEøC
1P!
!

$ # "

%"7SxYcyHB¨ØR©Ò;?PË79KNQB2P!»íIT`tkyf
R3I<@ KIF20A¯ RNA¯ð&ÂCKH÷³1¯pncgxYcyÚ¶HPÍ

I

R?¹<B2P!´"hjL¸Reuku%_adsGI2P:DC"ª¦ùÀµ9JHÞìúFxYcyª¦Aä7F;Q"xYcyGé>PT`tkyfH¨7õ<9å>P:
D76°;QB2P!xYcyH¨Rå>P@KG"Toll HÈGèHT]iafFER=T`tkyfD<B3I>P:DG4"hjËRÆO#QP:DC7SxYcyHB¨ØRà<B29EøC1P!UMIN PÍ¤ûR_adsGI"}FP+úbylYÂ
CKHï³pncgRXYdv<@7SpncgxYcyN8HPÍ¼¥7ëö7SRI=
KD<@Ï7SG52BûR;Q"Ãº;QB2P!:QNH1×Hð&ÂCKXYdv
ï³pncgxYcyN8Hë>PÍ¼¥

7ê@QP!»íI"B:Fã@+úC1

PîH7Sª¦ð&ÂHâ÷R53M3GÜ;Q@÷³xYcyn%v6N=D!C8PLHRÞì<BXYdv<@÷³1¯xYcyÚ¶HPÍúFB¨ØR¢þ>P:DGM
O"U7SHÔ¿N8H'G­£<B28@2D«4B2P!
&%+(Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T,/KIF20A, a kinesin involved with memNakamuraY : Downregulation of RAB6KIFL/
brane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancercell. Cancer Res 65$+*/)+,",**/#,(Taniuchi K, Furihata M, Saibara T : KIF20Amediated RNA granule transport systempromotes the invasiveness of pancreatic cancer cells. Neoplasia 2014, in press#/II clinical trial using-(Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H : Phase I/
HLAA24restricted peptide vaccine derived from KIF20A for patients with advanced
pancreatic cancer. J Transl Med 11 : 291"2013#.(Arens R,Schoenberger SP : Plasticity in programming of effector and memory CD8 T
cell formation. Immunol Rev 235$+0*),*/",*+*#

2 6 7 8 3 1 5 439,%Melief JM, van der Burg SH : Immunotherapy of established$pre%malignant disease
bysynthetic long peptide vaccines. Nat Rev Cancer 8#*,(&-'!)''/"-%Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K,
Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y : Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ Tcell epitopes : KIF20Aspecific CD4 + Tcell
immunity in patients with malignant tumor. Clin Cancer Res 19#+,'/&)'!)'(*".%Tomita Y, Nishimura Y : Long peptidebased cancer immunotherapy targeting tumor
antigenspecific CD4+ and CD8+ T cells. Oncoimmunology 2#0),/'!)'(*"

ß¦­ T Û\][

40

K¶BV THP-COP-14 éÚLn¹ë¥º!²

7/0 T +6&'%-"2!$
THP-COP-14 85#)39.4(1,*
ÕÁ
&%

¼ª,

0¡vÞLeqéÚH5V CHOP éÚ&CHOP-21'M T Û­\][K¶BVÐ¢ÀéI8T

WV;"PTCLs L CHOP-21 KSVåMÔêH1Ë®´æM0-+¿ÂI?WV!Pirarubicin&THP-ADR'M
doxorubicin IÎo@GÛÈNL_;³<"T-cell lymphoma cell line K96G doxorubicin SUhÀKÛÈNUPW"Ûh;y6>I; in vitro LZ$YHØ?WG6V!DLEQ"CHOP-21 L doxorubicin X THP-ADR K×@E¨&THP-COP-21'"¤J<IR CHOP-21 IÎo@Gë¥ÀKîVfÌ­M½6I«¾?WE!x¸ÑTM THP-COP LéyÂXQG/¡vpHéX7 THP-COP-14 éÚX}j@"ë¥ºÉ²X@GêJ~hXÆEEQ"ÄéÚX T Û­\][LÐ¢éIBO<"n¹ë¥ºÉ²X}j@E!

# ! $ "
ß¦­ T Û\][
uáckw­\][["ÏÇ^|&PTCL"nos'M4Û­\][Lâ0-+X°Q"

&AITL'MÄA<â/-+X°QV!èM6CWR(¯­ T Û\]

)H5U"K\][¯;Ò×LI?WG6V!T Û­\][LåM B Û

­SURàT:KîFG9U "CHOP éÚ&CHOP-21'XµI@EéHL1Ë®´æM
.'/-*0-+I?WG6V!B Û­\][K¶BV CD20 µH5V Rituximab Lë¥ÅÊ

KSUâ0ÖL/L§ìKä;ÆTWV©zH5U"{Ë T Û­\][][I B Û­\LåLMm<aÙIJFG6V!

T Û­\][

K¶BV

LÐ¢ÀéM CHOP-21 H5VI8TWV;"PTCLs L

CHOP-21 KSVåM1Ë®´æ0-+¿ÂIÔêH5V!Pirarubicin&THP-ADR'M doxorubicin L 4%
-O- »tµH5U".32-Ë¸KÝÜHmÍ?WEãH5V!THP-ADR M doxorubicin IÎo@GÛÈNL_;³<"T-cell lymphoma cell line K96G doxorubicin SUhÀKÛÈNUPW"Ûh;y6>I; in vitro LZ$YHØ?WG6V/'!
>WTL>ISU"CHOP-21 L doxorubicin X THP-ADR K×@E¨&THP-COP-21'"¤J<IR CHOP-21IÎo@Gë¥ÀKîVfÌ­M½6I«¾?WE!PE"íLß¦­ T Û\][ &PTCLs'K9=VÙÀÃK96GM THP-COP-21 M CHOP-21 I
Îo@Gr±slæM1.+I£FG6E;"®´æKMèH;TWJ:FE>I;Ø?WG6V0'!
>L>ISUi#M THP-COP LéyÂXQG/¡vpHéX7 THP-COP-14 é,dÓç¹q¹qb`qxg

Ò·ác¬Ègq

> _ ª , Q 8 X U

41ú^zD".40Q PTCLs ·0NÕ¸NDH/¶ØéÏ¨^°+DL9\!GQxRÎ)61,&CR rate 55,'"0êÿïÄÒ)24,"0êÌÄÒ)42,N PTCLs ·0PÕE\ÓQ/¶¨xNìDLVL-M8JH1'!y#RB]ZQxY["T ¢ûÂjlg
¯PÕE\ breakthrough ^}ëES@"CHOP-21 vs THP-COP-14 Q×/¶ØéÏ¨^
zDH!
!

"

ôÃ/3ê2%ôÃ/6ê0QP¥w§ÉM¿ÙC]H PTCLs ·0ÕDL THPCOP-14 ,úN CHOP-21 ,úQÿ£pv

ð/¶ØéÏ¨^«§E\!ï(¿ÙR¾èÊ

jlg¯ï({P<9LñÀQsï(qPY\Ûu¿Ù^9"PTCLs PçÜàO®ò¦h$b$PK9LQ"tË¼WóFL«§E\!üÿ£pv/¶ØéÏ¨PYJL
THP-COP-14 Q/êÿÐnÄÒ)3-,o¹>ÖC]\!
.'Í»PK9L¾èÊjlg¯ï({^üQøÔNE\!å{P<A\ênÂjlg¯½·0ÀR$4--*5--0N;Z]\!
/'Õ¸·0PK9L¾èÊjlg¯ï({§ÉP<9L PTCLs&PTCL, nos þR AITL þR ALK
rÂ ALCL'N¿ÙC]H¬Q:I".2¡%4-¡Q·0PK?"³òO informed consent^æH¹Mü/¶¨Pâ1^:!
0'·0â1/-.2ê1%/-.4ê0Q0ê
1'#î·0À1-02'â1·0ÀPK9Lü¨R"(THP-COP-14)Q%Â^ìäE\/¶ØéÏ¨M8\!2Ú/êÿÐnÄÒ)NÖ/êÿÐnÄÒ)^ÉÞD"³òOÅãM«§E\BN^#îNE\!
·0²Ç^0ê"ÝÈ^/êNÉÞE\!PTCLs PÕE\/êÿÐnÄÒ)R0-,ßãNù

C]L<[.'"2Ú/êÿÐnÄÒ)^0-,NÉÞE\!TH"P°+

DH THP-COP-14QØéÏ¨1'&7+.4'P<A\/êÿÐnÄÒ)R35,M8JHH
V"Ö/êÿÐnÄÒ)^3-,NDHº"öÑÞP<A\mai$2,QWNM"
í'·0À.40NE\N´.6-,^÷M?\!­Q|Æµ~0^*DL/-0^#î·0ÀNE\!
3'¨ª,PK9L
CHOP , ú Q doxorubicin ^ THP-ADR P õ  Q ¹"ª , e ` c k ^/± ý N D H(THP-COP-14),úTHR(CHOP-21),ú^3d$f§E\!v,úÛ8\9R
GQQ¤ÛP!Z=OïÁÐn &Progressve Disease ; PD'NOJH©áMÓ
Qª,^w;\BN^&E\!

Ý¦­ T ÙgjcMºBX THP-COP-14 íØNy¼î¥½!´

42

4'THP-COP-14(

pZ+.ÍÛM"0]%^!

THP-ADR/*mg&m,Cyclophosphamide

1/*mg&m

day 1

Vincristine+#.mg&m 'max ,#*mg&body(

day 1

Prednisolone+**mg&body

day 15day 1,,

5'CHOP21(pZ,+ÍÛM"0]%^!

Doxorubicin/*mg&m,Cyclophosphamide

1/*mg&m

day 1

Vincristine+#.mg&m 'max ,#*mg&body(

day 1

Prednisolone+**mg&body

day 15

day 1,,

1(End-point MH7IÚî¥N primary end point O,ÎÞµk¯·é"secondary end point O}³~
té:UP³¯·KBX!
2(Òè{Æ review MH7IÚNÇò§ïM:7IO"«ÁMqx±J@YDÒè¹Nehcf%bÜOdia\Z³§ïNÇò¢ëMu¡A"ªË²gjcÒèsM:7IÒè{Æ review Z>X!î¥N¯·t°OÒè{ÆÆz§ïMH7IBX!

3(Çò_j`%oÓê¼{Õ¶ÒmM:7I FAX MI§ïÇòZ8!Çò_j`%JOç¬ÑZä7IÄFMìQN|ÔZ7"¿ÈlQNñæZ8!
&%Úî¥O,*+.Î+MÇòwàÅJ6GD;"qàÅ±N×":UPÌâ
MBXÊ"Ã®MZåADDS",*+/Î.MÇòwàÅKwN×Zá

L=@YI7X!qàÅ±OªË²pN.¼{Òm:UPCNñ±"RDªË²g
jcÒèsNx±J6W"ÇòwO-ÎJNßÐ§ï¬É¾O¤ÖMrÏK
9VYX!
! $ # "
ÚMètZ7DE<¸¼LnZ7DE<RAD;[£{ÆíÀNvãM
ð©A¨?XKKTM"wNÂ»MH<:óP©A¨?RB!
('+(Tomita N, Motomura S, Hyo R, et al. Comparison of Peripheral Tcell Lymphomas andDiffuse Large Bcell Lymphoma. Cancer 109$++.0)/+",**1#,(Sato Y, Yamazaki K, Yasukawa K, et al. Cellular Uptake and Cytostatic Activity of Pirarubicin'THP(in TLymphoma Cells. J New Remedies & Clinics 48$1+)2"+333#

. 2 3 4 / - 1 0

43)%Mori M, Kitamura K, Masuda M, et al. Longterm results of a multicenter randomized,
comparative trial of modified CHOP versus THPCOP versus THPCOPE regimens inelderly patients with nonHodgkins lymphoma. Int J Hematol 81#(*,&+*!(''+"*%Tomita N, Kodama F, Tsuyama N, et al. Biweekly THPCOP therapy for newly diagnosed peripheral Tcell lymphoma. Hematol Oncol $in press%.

úÀÖâsÖÆKLã@Y HLA "°êöÅâµ4vÐ

44

4+/0('$/-7"1!#
HLA 5)23,0(&*6%.
ìÜ
&%

þ)

öÅâµ4vÐ8ò~IKY"=§*HMÿ)6VP²Óu×Í©ÃL63G"HLA xêM}Ãö4gh#8¡F7YýÖN65HNÌ¼MzT2X¯:K3!=WL"²Óir`gh#7W
MvÐT")ÏMsKJ7WvÐLDJXë;K3ÃTÌK:K3M8¤ÏH2Y!<MV4KÍJL6
3G"çæâµ4vÐd#c6VPvÐ3I>G"vÐ§èIb`qj_cj\ng[@3D} HLA"°êvÐ3QMå8¯REG3Y!<MvÐ3MDôN"+&&877Y-ºK T µ4Ëß¸[(AIBA",&:1*(I¯ELgh#8¡F7X"} HLA "°êvÐ3x$L¥5Y<IHT2Y8"-&ÂMás¿Lgh#7WMµ4G38®3U@3"KJMDô[;@Y!6

[í?G"<MvÐ23[=

WL!ó"tïñKTML@Y<IH"sÖ{ÆKÃLvÐM[àU>"´LFK8Y<I8å
H9Y!

# ! $ "
öÅâµ4vÐMò~IKYÀGð¬ÖMÿ)6VP²Óu×Í©MÍJH"}"'} HLA xêMòØKgh#83K3ÍJL63G"âµ4Mçæâµ4£I>G"} HLA "°êgh#U'}LäHMçævÐ3MýÖ8Ô

ñL8¹=ZG9

D+&'.&!x+M HLA xêMLävÐ[Ë;O"<ZWMvÐN HLA *xêMvÐIKY!
CMDS"øL} HLA "°êgh#L63G"ÈCM HLA xêgh#7WMvÐI%
>DÎ°L"vÐ/ãÿ)%graft-versus-leukemia effects ; GVL effects&83ýÖ[Á³@Y1±82Y+&,&!x2H"HLA *xêêvÐHNvÐ/MÙEM¯=U"øL}HLA "°êvÐL63GN"ÉÍMvÐ/ãÿ) graft-versus-host disease%GVHD&M!
ÍE8¯3<I8ü=ZG9D/&!
û"lpeo]Map#k7W"m^cMÄAÝÒò°¬¢%MHC&*xêvÐofp
L63G"vÐ¿LN7|BÕ¶[õ>BALvÐ>G"öÅ¬¢»LVEG"ÊÄ6VP
gh#MöÅ#~Ö T µ4[àÑ#~=BG"vÐ§M/,¿I34¦WZD¿Lb`q
j_cj\ng,**mg$kg [,­ùLõ>@Y<IH"<ZWMöÅ#~Ö T µ4[ÛéñLËH9Y<I[1±>D0&!<M"Ù2«6VP"GVHD 2«MÞ2«M7|?
8<÷H9Y<I8.7ED!x2"ÚÍÕ¨U¬ÆKªLè9K9[D@ T µ4
N"vÐ¿LöÅ¬¢»LVY#~NK:"#~àÑ>K3DSb`qj_cj\ngLÇÖNî:"0¾=ZY!>D8EG"CM§MvÐ§ÚÍUÆKKJLã@YvÐ§7|)è·½Fèèyw

{ÆKÕ¨4 V ½ B F . O K

45

GzºA5SB9T@/S%Ó(&!
J="yÒ9T=hi$ä³5GXsfkhëÔà©àF#¤4«/=L"æF/:=³5F'I"b^tl\clWphU/;SþE4«6"b^tl\clWphEP>@<xDÏUÄ7D/8B4/3>@/S!
~0AFFË

B:@G")'',ýEosdqXBbXgsF_s$nFøEP>@"

3DRõFÁ/°Õ(ÿóÝÈîEPSyÒ¥èDb^tl\clWphU?/=}HLA $­ïyÒFØÚ43¯9T=-&!8F«94®.

AG"× GVHD GòAA.>=4"²#A

êB:@µ>=!

öAG87Aæ·ÛEÜ7@")''-ýPRyÒ¥èDb^tl\clWphU?/=
} HLA $­ïyÒU¨>@/S!ÐF!3Q"öAG"«/²#AF®.F=L"(&yÒÝÈîF")&³5£G;I@9Í³5U¶?"*&yÒ¥b^tl\clWp
hF¢DDCFù¿FCU¨>@5=!
&EP>@"öE27SÝ§5Fé!ãFjYteg¹¡%OCU91%Ìü&¬(++-&} HLA $­ïyÒE9Í³5U?/S8BEP>@"Å/EÙð4í2A5S8BU
ü:=!9QE"¸ô?DFyÒ¥F[uh]auèDB4U?/S8BEP>@"GVHD
F#ÎA"ÆÎõM>%w`ugt$s:0S8BM/3>=!:3:D4Q"öFjY
teg¹¡AG"yÒ»E{óD(ÎGFyÒ¥FÙåAG6:6D3>=!9QE"ÝÈîE°ÕÿóÝÈîDFmcslWuU?/=Ñ­G"BK ZYscEPSÇ×IH|4«AE#Î:=!
8FP0D"!3Q±F

AG"8TQFjYteg¹¡FUMBEÝÈî3Q

ATG%anti-thymoglobulin&2PH"mcslWuU´É:@CU1=!9QE"ý"×",E2/@"øÃä³5yÒ¥E)Êµå,1%MRD&U+:@"âEhi$ruj;ñU¨08B4=¥FÞE?D4S8B4¾9T@2R('&"²#GEç;SyÒ¥Fhi$ruj;ñB4UáKûT@"} HLA $­ïøÃ9Í³5yÒFé)ã¹¡U¨/"<Fvß×NÀEç;S<¦×U÷;S!
10"34.,'&%(
ì·Ûé!ãFË¹¡:*ÎGÖ#+)G2)-5+$!#*/
Â@+ª:
yÒ¥(''úAFÙðÙå­-¼ó+ª:(&yÒ¥(ýAFßÙåA2PH"²#A

¢}oh\¼=9D HLA ¨t46

odw­].*]r-¦;>©u§{®¸/*^|«"£|«¸
0*o`¬A;>if"cJVWA;>if
1*kj@± GVHD >ª"
2*}¹g»¡
3*wm$m$HGYMe>§bt
4*²_us%$!#)-/#ql´if
ºif%¥r(.,-4¦2p/,¤ºif%¥r(.,-5¦2p/,¤qlif%2¦"&'(!#*]%X[ySYPWR[)-1mg'm.+.`'¤E.¤f</,mg'm.+-`'¤E0¤"VYSFW[)-,,mg'm. E-¤f*E¶7
f*"LOWR[).6'm.+.`'¤E.¤f*D).*!LKZSIMSFTQ?]r day 3"4 =.1mg'kg"n1,mg'kg µ)-*]N&M%º; G-CSF)granulocyte-colony stimulating factor*;v~8:°odw­
E¶7D!
k GVHD ´¯%²_·x?OKZXUM),#,/mg'kg'day*< MMF/g'day)-,,,mg+/`'¤;az*E]r1¤³BCaz9D!

-8Fludarabine* 15 mg/m2 x2
Ara-C

2 g/m2 x2

Fludarabine

30 mg/m2

Melphalan

100 mg/m2

Cy

25 mg/kg-7-6 -5 -4 -3 -2 -1

0

1

2

3

4

↓

↓

↓↓ ↓↓
↓↓ ↓↓
↓

↓

↓

↓
↓

↓
PBSCT

*fludarabine ߪ Ara-C ߩ㧠ᤨ㑆ߦᛩਈ ‫ޔ‬Cy: cyclophosphamide‫ޔ‬PBSCT:ᧃ᪳ⴊᐙ⚦⢩⒖ᬀ
&"#%'$(!FA-FMel

= a Û q P 7 Y U

47-1/&'(!*+).54%#"$Multi-color s  & j d o y & m ; Z R"2 s PCR O Z ] 4 Ì  6 Ô 4 Þ Ò S X WT1mRNA NMTÔw&f&`i8J MRD `ñ¿O2¨3Ose&BJ"MRD =k÷BEîÇQ"`löÐ/Ö¿Oh~&p!íP GVHD =EëBN8@L`?BEPF"ñPpq&Z\|rªd0` dose-escalation YKÃ9³K7]!
2

3\¸«Q¸«&_*=Û÷ÿµ¦÷ázO#C] HLA GÇ,:àÿµ¡ÏZñ+L
BJ%ÑÕp%%¸«tnPé?`â?J8](é?IÆ035/)!tné?¿Z\"Uø04@//¶PÙ5KP7yõQ/2wK7]!@xP/*Q24Î(H/5,4/)"÷WQ)÷5w"æ÷5w"Ý¢P<cQ"©÷Êô÷DµN4w"©÷|r÷
DµN4w"Êô±øëÀ°/w"^÷Êô÷DµN/wK7GE!TE"ñÙK6w"

Q4wK"Gõí=K

w

wK7GE!

\Ø¹K#ìLN]¢ßQ"Ý¢ð$=8ëw=">"ñ¿þ¨PºÝ¢PóÃ$ÍE
OZ]×[PC÷=Å8@L=eýA^]!ZGJ"\Ø¹KPü÷O¤BJQ"ù.P
ü;ZR"ñ¿/..>TKPþ¨×[(ºÝ¢PóÃ$ÍBOZ]×[`ç>)="vúCëw/O;?]EùO8P0ÄTQO§I>òm¯£P¾=0.-íLNGEîÇOQ\Ø¹`'/ÖC]@LBJ8]!¼Ù5KQ"ù.Pü;ZR"ñ¿/..>TKPþ¨×
1-K7[Q"MCëw/0wK0Úù.Püw/wK7\"òm¯£P¾Q;ZD,5#\"\Ø¹P²!QCLF(BJ8]!
0,

VKPuè¸«LBJQ"ûäBEZ9O0..6@Ov}nzcLkco}Ph}&tP­:¸«=XÉA^J8]!%LN\"ã8P GVHD Eë`·ABJ"¡ÏZ»OQÊô=i8[^J;\"ñ¿%skgselsbxpQ"kco}Ph}&tQ1>a;Z
R"2>aO³/..mg'kg"v}nzch}&tQ1>aO³3.mg'kg P9f=Ã_^J8]!
©÷ GVHD PvúEëoQh~&p!-"=12-K7\"1ïP HLA ,Pñ~u}PE
ëoK"KïOio&}=rÁ7]L½:]!@PEV"/@PKÍE×[oQ/3-Lr
ÁK7GE!B<BN=["ÍEo=3/-LÅ>"Å8ÍEoPÈR=&LBJÓGEL8:]´K7GE!
@PXÉ<[";OñÙKwNMPe¿PrPµ÷Ý¢KQ"Å8ÍEoPÈR

PEVO"ñûå+P®=LjLÂ:[^E!\¸«KWñûå+P®`ÃGJ8]="%L:hOco{mPh}&t<[W]êÿµ¡ÏZ`i8"<Hñûå+P®
BEµ HLA GÇ,ñPXÉ=7\"´LBJQù.oQb&N>rÁK"]êÿµ¡ÏZ`i8EîÇOQ¥T^]|rªPs=ÊôOJSJ"8EV"GVHD PEëo=Å
>N]·A=7]="©÷ GHVD PEëoW¬gH

K7GE@L=ÜA^J8]//)!

Ë¿"ëw`-úBJ"ñ¿%skgselsbxp`i8Eµ HLA GÇ,ñO½ª¯zjªØL°AW HLA Áµ¼¯xÈl¡

48

85G"¨­´}»S¯xÈ:¨IÊN

H"l¡ÎLJNT6Km~

ZÏ7W9ZÄq@G5<ÂÑ:4WI7G5W!
! $ # "
É|O¾N»9FqKÅÃ¸ÖKJIOkKV"<9UYXG;CÍH
4W"`_ie]ae\fcZ¶A>IH"ÓN¼¯Èl¡ÇIO®<kKECl¡¬ÕZr¿L@Ct{¸Kl¡ÆÇI7PA!>N«sO"Ì/*¾Rl¡NËnÒ©
I@GN`_ie]ae\fcNvÀZ·QW>IK<EG;C|CDN³PMº×N
L«VÔEG5WI7PA!`_ie]ae\fcBNRNTVR">Nl¡Ç9U7
G;C£@5¼¯Èl¡Nh^dbg:"¦¹@G5<>IZ¢TV{±@G5P
A!
'&

É|L?pVP@Co²Ç§:[w¸Ö|²NyuÐL¤¥@
=PA!
(

%

+(Burroughs LM, ODonnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA
matched related, unrelated, or HLAhaploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lym$+,13)21#
phoma. Biol Blood Marrow Transplant. 2008 ; 14'++(,(Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from.
family members other than HLAidentical siblings over the last decade'+33+),***($+/.+)1#
Blood. ,**- ; 102'.(-(Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed byunmanipulated HLAmismatched&haploidentical blood and marrow transplantation canachieve comparable outcomes with HLAidentical sibling transplantation.Blood. ,**0;$-*0/)1-#
107'2(.(Aversa F, Terenzi A, Tabilio A, et al. Full haplotypemismatched hematopoietic stem
cell transplantation : a phase II study in patients with acute leukemia at high risk of re$-..1)/.#
lapse.J ClinOncol. ,**/ ; 23'+/(/(Atsuta Y, Suzuki R, NagamuraInoue T, et al ; Japan Cord Blood Bank Network. Diseasespecific analyses of unrelated cord blood transplantation compared with unrelatedbone marrow transplantation in adult patients with acute leukemia. Blood. ,**3 Feb$+0-+)2#
19%113'2(0(Takahashi S, Ooi J, Tomonari A, et al. Comparative singleinstitute analysis of cord
blood transplantation from unrelated donors with bone marrow or peripheral blood2 6 7 8 3 1 5 449

stemcell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. )''. Feb (#109$*%"(*))&*'!
.%Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bonemarrow transplantation as treatment for acute leukaemia.Lancet. (0/*(0#1$/*),%"-()&,!
/%Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ.Durable engraftment of major histocompatibility complexincompatible cells after nonmyeloablative conditioning withfludarabine, lowdose total body irradiation, and posttransplantationcyclophosphamide.
"*+,-&-+!
Blood. )''( Dec (#98$()%0%Luznik L, ODonnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, BolañosMeade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF,
Jones RJ, Fuchs EJ.HLAhaploidentical bone marrow transplantation for hematologic
malignancies using nonmyeloablative conditioning and highdose, posttransplantation"-+(&,'!
cyclophosphamide. Biol Blood Marrow Transplant. )''/ Jun#14$-%('%Dominietto A, Pozzi S, Miglino M, Albarracin F, Piaggio G, Bertolotti F, Grasso R, Zupo
S, Raiola AM, Gobbi M, Frassoni F, Bacigalupo A. Donorlymphocyteinfusions for the"treatment of minimal residual disease in acuteleukemia.Blood. )''. Jun (#109$((%,'-*&+!
((%Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE,
Bashey A. HaploidenticalTransplantation Using T CellReplete Peripheral Blood StemCells and Myeloablative Conditioning in Patients with HighRisk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse
Free Survival : Results of a Prospective Phase II Trial.Biol Blood Marrow Transplant.
)'()#18$()%"(/,0&--!

MDS Dê7Qß EPO )E¢#

50

9=.4?<83"B!$@1&*'+)&(,0D#E5-A>"B!$/2%6C!$F;:7
'ñ
&%

ìÏ(

¯ÑzÔÇ©&MDS'E½KYi_mrF6Òç´5"9ECOFS/<?,C,!<£@F"

MDS E%ÓTó¶7Q¼@°úC½KTÛð7Q3A0*ACQ3AT?º5:!9E:LDéùDFx
E*=E£T¬<:!s MDS ¿E EPO ôTäø5"2¡0­ÿDCQIB EPO ô0ÈÆ7QA,à0+Q3AT¾5:!t¦´¬SR?,QMENPßD EPO T!F7Q3A@B¡áLE¥Ä0K3L
Q/A,-MÅ£TJw5:!uG%C MDS ÇNE|þ¹,¦iqhUWoTÖ5"×¡ã¡D7
Q|þ¹E,¦0 MDS EÎûD-,â54ODÎû7QA¥ÄDü6Q3AT¾5"EPO 3ÓlZeb
k0|þ¹pjo@Õ6?,Q3AT¾5:!v DNA lco

Ý³@+QV^_c`rE½KD3ÓA

C<:ÇNE\fkTÖ5"V^_c`r3ÓDP7Q|þ¹8zTó¶59E©9T$ø5:!

# ! $ "¯ÑzÔÇ©&myelodysplastic syndrome$MDS'F"ã¡3ÜAÓ+¡1HEÎ
ûT%õA7QÇ©@+Q!MDS E1ë#ÇÊF/ÉDè±@+Q:LD"MDS EÍKF§%EÇNDê5?½KE?ùTØø5?ÎLQ0I0+Q!MDS EMÅF"ã¡3Ü
DN<?2¡#Â¡#ÚCBEÇÊT÷5 QOL Eö0@ïACQöna[A"Ó+¡1HÎû7Q®0­1Õ>E¨0ö7Q­na[Dí74RQ!3E-;"­na[Dê5?Fã¡²;{ËM51F9Eú0C2RG DNA lco

Ý³TM;,QA,-Vo]nbk0IJJ5?,Q!~:"öna[Dê7Q½KF/ÉD6¸@+Q)'!4OD½KYi_mrECÙÃyD5?F­,pjoEXgdra0C1"ò&Ð)'

î(à»¤@¢#4R:Þª¹D>,?Vo]nbk0

ø4R?,Q!4OD"ön

a[ MDS Dê7Q½KYi_mrF"·²;AEN-CâÌEå,²;~.DµH7QMEAFzCP%õùCµHýTD7Q!3ROE3AT«.®S8QA"½KEµH%ÓD
6:¹Tó¶5?"9ROE¹ED=DN<?½KÛðT¬-¼0ÁI@+Q!<£@F"9EN-C¹Eó¶T»K:!

("í}54æ1¡ÀQ&

4 U ¡ ò E / N J

51

0! NCCN "2/#%1,)' MDS $.3&-(,*+

1!MDS '$%):4=9&*.+/-*,0Ñg]Y MDS E1="á4¦ÈAC>?0Q¥DÉ:QÉqF

òæA9?í4

èACQ!939íFÓw¬DOQ°â¾$«|$m¼¶4ìÌACQ<K"ÃT
Ä±:Q¡òæE{Ú4ÞðACQ!¡òXc[fjACQE4hbgaea"Wg]idW_j'EPO(º"ëpñµ"VZ[_\j@/Q!hbgaea4ÉªACQË¼¯ÈÏõ4£9< MDS FÖè@F¨C5rT§6Q¥F¨C0!EPO F»EãtÁ®n@/P"²Â@¹·8RQ<KD²â¾DÛ0 EPO E¹4Ñs:QAáACQ<K'²¶á("EPO ºF7EàÊDÉ9?ïuÙ@/Q!939"MDS D26
QáDÉ9?z½vTî:Q<K¡4SR"ILC5ïuÙACQJ@/Q!
2!MDS '$%) EPO ;(5<"8763#
MDS D26Q EPO ºE¿DF"íô4¨C07A"¸ EPO Í4ÑÍ'-**U&Lêé(@/Q4À:Q+(!939"7E EPO ÍE­Té<:¥4èçE MDS E
¥E1=BRHBÆ:QE3"A01`%^FÆ9C0!;7@ÕoDÐoÎEÑg]YMDS E©ó'International Prognostic Scoring System : low I<F intermediate 1(E1="Hb Í.g&dL êéE©ó+*óTÉªA9?"¸ EPO ÍTÅÒ9<!¸ EPO ØÔF
SRL ¢y¤D?ÅÒ9<,(!EPO ÍF IPSS E low AÜG? Int1 @îlDÍ@/>*-(!I<"íôEÇ0¥Eå4Í@/><'p)*#*-(!¶ä"´xE<'p)*#~M¼¯È}DOQg]Y"WPSS ßAEÀF×KC3><'³+(!íÝkÆóMDS Az:Iw] EPO SB`52

I# P876 MDS 1*,4 EPO O2BQ%"IPSS 876134 EPO O&"S@;MK134 EPO O'"EJ<?=D/ EPO O2L> ("IPSS 876134 EPO O>C"EPO }? Hb BYABxZKD<&R2(*#
1.'!,*~"EPO).**U$L C+*"EPO),**U$L C26X9<!_MyB+,Kzq?9<T^v>C"EPO(.**U$L C Hb(0#/g$dL"EPO(,**U$L C Hb(1#*g$dL Ax9<&s-'!

B_VhjB Hb }C/%0g$dL >3H7B}CUWFH46"x:I EPO }C.**U$L LrK
l:7?Kc5I?"B\n>_KVh:IpC EPO ugBbQ6]{m@47?6lf8JI!;B<D"_Kid8J=4@4pE[D"w]B EPO ugBO6
eaB`R|>3I?c5GJ<!
%

S@FCGT!A#N:9H"&

S@FC+-5.0)GT

_id6@4p>C"Hb }6P6I?"Epo Bzt}6BNkxZ>ro:I
I$ MDS 1*,4 Hb O/ EPO O2L>%"S@;MGT &"S@R;MGT

; a ¾ 6 P 5 Y U

53*!<)(' MDS #;"%:/ EPO 83$4@&0>"%B761
ÏPQ".P¸`êHK EPO Ø³`¶0B]M67¾6Ü4LQ EPO P/ªÖ`ø[^N6Ð®;è6?M`¿B!E?L MDS OéAKâO)Hb3&4g%dL Pí
L*EPO Ø³`¸B]?ML".ä7`¦[B?M;È1]PLQN6:M67

Û`

3K"8Ì¡`AF)Ô0*!»¤phd|Qx|mwëúãMA"primary endpointQ\#>¨.üP.ä7PÿL5]!õÉ"½æ EPO Ø³L5]mztuen|;'£Ç²@^"»¤O¶0L<]?M;¢°T^K6F;"'£Íû;ï^FFV"?P8Ì¡QÃºO~B?M;È1N:HF!?P»¤LQ secondaryöP¦ËXÖý!SP~¬2`

endpoint MAK"çP÷B]?M`AF!?^Q"+MDS O96KâO ESA Ø³`¸B]?ML"MDS PÀß·`&@D]?M;È1]:,M67´Û`÷B]WPL5\"EPªP/+Qà=5!

Î@^K6N6!

9,*( MDS #8"%7. EPO 61$2;&/:"%<430$+)'-+!EPO -A,=5$?2.9"!%$
MDS O96K"EPO ;­îL5]OW::_[CÚå;á@^K6]?M;-[:MNHF;"EPÊQ_:HK6N6!E^`-B]?MQ"EPO Ø³"ÖX"/ª:;+ªB]¼OéB]¥P-OIN;]M«8"EPO 5ó¹Pþ§X&}Pìµ`¬HF!
#!&'ó¹joqQ NCBI P GEO database Oô;@^K6]p$ljoq'GSE19429(`W
G6F!?^Q.3/,P MDS ÅM.2,PÑÓP¯Õ:["åÞ±)OãõB]$)CD34+ ` v $ f $ M A K k $ q A F*` Ý % A K"RNA ` ð È A K Affymetrix Ä
GeneChip Human Genome U133 Plus 2.0 arrays OKþ§Ù`¬HFWPL5]0*!d|l$roqÏO©@^K6]×Pc{dp$l).CEL sbdz*MÅPÂÒ(`ÆøA"
WHO $9OJ6KÅ`òyig)refractory anemia : RA, refractory anemia withring sideroblasts : RARS*"­yig)refractory anemia with excess of blasts : RAEB1,
RAEB2*MÁ%A"?^[`®_DK MDS Pyig*Pó¹þ§Pùñ`ÙAF!c{.#)http://www.rproject.org/index.html*9ZR gene set enrichmentdÙQ R version /#analysis : GSEA)http://www.broadinstitute.org/gsea/index.jsp*`WG6K¬HF)Ô1*!

MDS 9s2BqT EPO N~:[{

54

MDS &)'E"xKGF#MDS$RA/RARS%8`KGF#MDS$RAEB%9Uf/3!
ozLybHIJ-A"mYVrY9Q2B8cDCBLybHIJEve13!
8" MDS &$%):2451;7<6!39'=*!

"!$#GSEA 7;"}k9S5+6LybHIJE=8>3 curated gene set Ea2B087"
t9@BLyb]:}wE"*BLybHIJ9R=CB

j:Lyb:]:X^-A

2B08.eB!Ol:3>9"mYVrY9QW:*BLybHIJEnu13!
xKGF MDS ;`KGF MDS 8<6mYVrY9Q2BLyb:];h16+
3!M"|:OlEZgd8:P9,+6?_43."p916xKGF MDS :.Zgd8P16mYVrYQLyb:];`+X^.\AC3$i(%!

8# MDS '-+0&()1;7,./'<639>

2 X ¡ ö F , P L

55

$!-.
»ÕBëR1ED?<Q.E"MDS E0-AãF±EÆ7A· EPO ÌF®«2
LRUT!5UG²ÁEQTãIFÇ©~GÖ-A-TNFF"ç2 EPO Eàn
B3A-D-5CW¢7A-T!MDS F RA$RARS FËxBG"EPO Eàn7AºÂWTkÔFßGÀq7A-T!717"RAEB FËxE±Ò8TC"EPO 2ÌB,TEN11VR9ºÂ}økÔFßG¥8T!8DV>"8DV> MDS FãF±G"'EPO än¶fZc`eF±Ò(C-.ÃìWï8T2V1?<%³+&!5
UEG MDS E0-A EPO ^[bgFóµ~2Ö-A-TrÝ¶2,T!<=7"RAEB
E±Ò7<¯EG"´FÀq2LRUT<Mºt»ç2¿ÆÑEª7ATrÝ¶2/RUT!;F<M"ºt»çE0-A×ñFÕW.5C2èK7-!éu¹FwÓC7A"EPO oõF^[bgÉÞF{¶pWÕ8T5CKBG§ôD
1?<!K<"5F£B7<çGÂ»ç%CD34+&B,S"º»çIFåpFªC-.~¨WáÐB3A-D-ÓB,T!

MDS &8+&1.!EPO 3+0*&(')%/1C-.ÃìW@;FfZc`eWuë8T5CG"EPO ¸än¶O"ï÷2êp8TEÆ8TmFëE@D2T!
2" MDS &15$3+*4+(607,%)#'-/)!DNA '&(-4.0$7,3#/"%+628*$51"!2,
6REs#G MDS EÆ7AQ4N>-RUT¡öC7A"DNA fagp½yB,TY]^a_hFò~¨E}ð8TkÔE@-AFÕW?<!vGÙE"Y]^a_hän¶fZc`eEÎí7<!D:DRH DNA fagp½yFï¶Gî)ÛC6UA0
S"lÈ¾7<¯BNÄ4F¯än¶CDT1RB,T!
#!45
ÅÑEG"s#27<|¤1R"Y]^a_h¡ö2¾7<EÜ7<%Y]^a_hEQT¡öB PR i®N74G SD+HI 2ØRU<NFF"¼WÚM<&*¬÷WÆ­C7A"¡ö»CY]^a_h¡öän¶CD?<C3F¦ùçF\deWÍ§7"â
zW?<!¼

FkÔæjWÏJ"°Ê

Câz8T5CB"MDS FmCDTkÔ

BGD4"Y]^a_h¡öän¶E}ð8TkÔWÏJT5C2B3T!Ion Proton%Life

MDS ?t5IsZ EPO Vy@^x

56

technologies!$KD8.< Whole exome sequence Ka."Ion PGM ?< deep sequencing
Ka97#o+$!

7"()*,+-;/8.:5$94!60$='!

"!$#LMNPOQhdrg@B_:097&,*Swe#'()Uk$@RK"SNPs ?FIq~l\K/3>."Swe@[{E|?Y;.<%+Swe?`HbBKa97!3JG@Sw
eA Ion PGM KD8.< Deep Sequencing Ka."WzKa97!6@]T"*:@Swe
1vj4J7!3JG@SweRnA"MDS ?/.<_GJID@=A>.7C"MDS @}m?X5ISwe=A>2"LMNPOQ@up?X5ISwe=-If1ic4J7
#o,$
!

7#

()*,+-;/8.:5$1<.:5$2&3%

6 [  Ú I 1 T P

57

"!#$
";YVIÎf½I]d%ce^4UL shRNA construct I­Z§QD4W"invitro E©zÞIÐqZÖ2Al£ÅIzStÄØ«IzEI\_`bae´¬iÓÒZoÃ>D2X!@I|k\_`baeMI´¬HsÔ>D2X;F6oÃÙYK"Í
p¼G´¬itZ}À>"ÚÈ¼IÅHCG:X;F6jÄF

3VYX!

! $ # "
Ñ~wEJ"ÌE³ÕG MDS IÉµIg·Z17V5H?N8m¯ZBA6"=VG
X³ªÝEI}¡FÜH49X¡6Ç×Êj{E1X!R MDS I¦ÚI¢H9
D¿ÛZ²9D28Ç×61X!
Ñ~wI<ÂZº2A±ÏËyF"xÁ~wI¾¶&¹'vÆ°®"u°®"»Ñ¨°®Hr¥>¢:X!
H";I~wH<hº7O>A"6[p¼Ú~w¸InÕH¤8r¥>¢:X!
&%*'NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes V.1. 2015#+)*-#+'HellstromLindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model fortreating the anaemia of myelodysplastic syndromes with erythropoietin + granulocytecolonystimulating factor : significant effects on quality of life. Br J Haematol 120$*),0(-/"+)),#,'Nakazaki K, Nannya Y, & Kurokawa M Distribution of serum erythropoietin levels inlower risk myelodysplastic syndrome cases with anemia. Int J Hematol 99$.,(/"+)*-#-'Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in
myelodysplastic syndrome hematopoietic stem cells. Leukemia 24$0./(/-"+)*)#

58

ÿ§Ì¥3:J,3GðXÃïª=>×3G´§?]}>z3G

A7<6DF(C#'4@-;?8G%=#'
4:7&.0%/#'21
àÛË
-*

Ù`;%

`ñ>°¢Ánª"¸_ª>Øö0HGXÃïª=@'ÓXÆÔ1;ÍÆÔ1?,°0.ð?~,é:(G/;,ÝEH9)G,"í"ÿ§Ì´§>DFûµ?Óg=.ª=Âk,EH6;3Gþ,0HG!5/:l$@ÿ§Ì¥3:J,3Gð°¢XÃïª=>×3G´§?YÍÃ;,ÃJ(E+>3G6A>7²

Jm2Z16!7²

?QOLV@Ð|ÚWÑ7²

;1"Î¼

vå>½Ü,tä0Hÿ§Ì¥3:J,3GXÃïª=J×¶;1"¨0MVSTLVR@&í'ÓXÆÔ1"ù¤åMVSTLVRJ&íÍÆÔ1"8Ç,r¡¶ðÆ1;Èä16!|yè>&'9?µ9æ<JK:)G!$:@$7²

?s0;¾áº>8)9oÉ3G!

% # & $°¢Ánª"¸_ª@°¢ïª=?¸[JÊA"ÿ§Ì#fv3"x«ÃJ,3G/;+E©®3">g*9ÿ§Ì¥3;fv3"J{A6¬vå¥3,IH9-6!°¢ïª=?¥
3*õ@hî=FÆÔ1JAG/;:(G,"°¢Å¹Î¼?ÿ§Ìx«Ã@Ä¿DFB."ìÝ6·r"èúô·r"ßu·r"ê¤,K"Äà·r=<?ó|,r¡¶,ÝEH9)G!/?6A¥3k>·?=)ò\:ÒÌ5C`pÌ5?ã"´§ò\?­°f"(G)@´§q£|?ÞcJ*å;19ðUPN>e29ÿ§Ì¥3Ì5C´§ò\?Ï
ýfJÀ76¥3,7²

;19IH9-6!

`!"°¢Ánª"¸_ª@`ñ>¥3UPNJ+I4'ÓXÆÔ1;ÍÆÔ1?,°0.ð?~,é:(G/;,Ö)!¯ð¥3>ÿ§Ì¥3J/)9)=)ë.¢:@ÿ§Ì¥3;¦i%³

w#^»~dÙ5fv3">DFà|?ª=Â,çEHGhîÃ,(G;?þB(G,"Ò29ð9?¥3@â¹é:(F-@A9ø4:(G!í"ðïª=>×19ÿ§Ì´§>DFûµ?Óg=.ª=Âk,çEH6;3Gþ,0HG!1+1"ðïª=>×3G´§>z19)&>m0H67²

@A

9±=."5?]}@(E+:=)!5/:l$@ÿ§Ì¥3:J,1"Õ?¥3:@Âø
î;*EHGðïª=>×3G´§?]}J(E+>3G6A>$Jm16!
"!.,+)('"!E953&B>$+*),$7²

?*å@ÿ§Ì¥3:J,3GðXÃïª=>×19´§J/)6~¥3%ü2/<B÷abª=èj

7 S  " F 2 L I

59

RD3">Fü¹Cb¿¹Rìj=P:CB2P!XWT\GÁzË`ÃC<?!
"!=?48!
*¥³EèÂÕ£¤D3<º7;Q"À°sÖEæ*7rÓ<A3P!

!
+Ø)àFä(7+.ùø!

,!

æEÈ=Pó¾"7m|E;QA3P!

!

æÞ2P3G¼µE*FèRãK"ÆF"ôõBG¸íåC4NQP!

.
!

¥oF¿æ©6N/Vc­7~m<A3P!

!
/

Performance status 7)6N+B2P!

0!

ö´<8GÊÌ6Nò§EMPÜd7ÝNQA3P!

#!:148*!

uÛ¹F¢ð7SRü=P!

+!

â±Ò<8G¡áÒFî´!

!
,>FÆ"{ÎÚ&g'7í×ÚCéÏ<?v!

$!A.6BþU\Z[T\Y%*äúÄaºÅ!!
ïÖU\Z[T\Y%*ä¿ºÅ!"&»üq«èº!&ÞñêsÖe¯"æx¬q"
Ñå¬q"ß7S'!
%!7E5/2C*!

µn&primitive neuroectodermal tumor : PNET RyJ'
1Gy"+)ñ
]¥o"B}¦©7©;Q?$hpFè%}¦©¾#,/Gy&*o*#t'!¥o"B.)Gy ÔÙF©¾#7©;QA3Pkå¹72O"&»©¾#G
1/Gy CDP!
.Gy"*+ñt'!¥o"B¿Ò·²~^µ÷çè%¿Ò·²~©¾#*1Gy&*o*#©*1Gy 6N+-Gy 7©;QA3Pkå¹78"¿Ò·²~EÈ<AG&»¾#7,/Gy 6N-+Gy CDP!*}¦EG¥o".)Gy ÔÙ©;QA3PC4NQPF
B"&»¾#G/1Gy CDP!
1Gy"+)ñ
_¥o"B}¦©7©;Q?$hpFè%}¦©¾#,/Gy&*o*#t'!¥o"B*1Gy 6N+-Gy F©¾#7©;QA3Pkå¹72O"&»¾#G.-Gy 6N/)Gy EDP!

+!

­f%}¦©¾#.-Gy&*o*#1Gy",)ñt'!
¥o"Bû.-Gy F©¾#7©;QA3Pkå¹72O"û*)1Gy F©¾#
EDP!

&!;F<5%ýÓØ)¶*/'!"E59PzÉ*äúÄaºÅ!-.("hÐ*äúÄ)."£%1)(C<"û*)(FÍÿª'R
aºÅ!,)("αerror )#S@®Fëþ

ª'¶R*/'C£<?!
'!907E-3+(;F>*@,)2D
ö{È«FÇCHQP¨µnGó¾$is"õw¹*B2OplÖ½

Ü­ìñRå;OÍY§ËóE³;OF[uEr;Ox60

"Ü­ì"fnìÞ3MDOn½ìRD1!=F"kìGWVU×ïEe
:>°Úfì4QP%¤(&"Æç%)ãâ&BGÐsÄ§Rë9AkìE2
0A4S¥ÅÀæ%¥¹&RØè9>zffnìÞ2LHgá~qß\¢vcµîfnìÞRÃÇ;O7CBÜ­ìRkÑ;O¬êRC?>!_ÝB)Z¡FBGÒWVU{E³9A¯Ë¯©¥ELOÜ­ì­îC¥¹RØè9>zffnìÞR
D0"WVU{E³9AGÖ¦kgá~qß\¢vcµîfnìÞ%tandem PBSCT&
RÃÇ;O7CELNìzfR¤?>!
ÒWVU{WVU{¥àÌRÎQD0%.'& ¥àÌRÎ1%.(Z¡&
¥i
¥i

Æç
)ãâp@¥i I > G
PNETÍÉð)ãâ"¾\/N%Chang ×ïE26O.($.)&F0<P3_@Z¡Rå;
OKFRWVU"=PZlRÒWVUC){E×6>!
6!

517.3&9%(8<,2>&#$(+*);?

Regimen ,#VCR//CDDP//CPA//VP16//ITMTX
Regimen -#VCR//CDDP//CPA//ITMTX
HD1%µîfnìÞ(&#TEPA//LPAM or Bu//LPAM or TOPO//LPAM//CPA
HD2#CDDP//CPA//VP16 +/
/ ITMTX
6":-&#$(517.3&9%(402>'+*)<2>/=.

,"!48-0)*6326511/(&'"7#21$+%"#!
*+T·!ò¿"Â»E`5²5otÔí"[m%|ä|&RÈJ>>J®^R£9>!h±¡"bµËÏwÂºÕEÊßRÎ1«y§ÓÛRÈJÁajÇaCD?>!
X¯¼48P"ªÙHE¸dÓé£¶EA´}¨¡]%anaplastic ependymoma&

: Y  Ý I 6 R N

61F¶=WB!­|i±¶EJÃ¤ÇÌG; Chang Éà'5Éà(EJ5+E6CB!
|goÝÏ'etoposide, cyclophosphamide, cisplatin(XCB:¯}A@"temozolomideÊÚÍ¬Ý'u boost$0/Gy&.+fr(XCB!lÍ¬Ý9T,-Zy|HuÍ¬ÝIßcmE6Vª¡Hµ~vÒXsOÈ¢IÃ¤ÇÌ'Ä(XÀPB'.(!
¼b½I|"Th,,L3 H?VÃ¤ÇÌH´>DuÍ¬ÝÏX°¬Þ0+Gy',l¬Þ-Gy"-0Ép(ECB!=THÂÐ²µHÅ7»XÊÄ>"ãIÂÐ¥ÉI²µ

8SKã¾xXÀPB!uH´>D γknife X¸h>B|"ä¡ª¡H?VÃ¤ÇÌH´>DuÍ¬ÝÏX°¬Þ3Gy',l(E¸h>B!Í¬Ý|"IÛ£J½TWBQIIä¡ÇÌLI.Zy|H{ÇHSUeÓ=WB!lÄ9TÑMEI¦³tqJ2ZyE6CB!"Í¬|HÝHrâ>BÕT9G×n

JÀPG9CB!

G% EX#=RF4A$.7LC:'$BR?!($YHQ@SU!)$Th11L3 -<,/Q@ISU#!4;27.9*%$&%305+1')"(%-:/8,6á¨:Ø¹XflCB{dXz?VBP"«H8<V¡j\_%^I|Îºk§XCB!`][ËÝ¥©X/H?'/(!

-ÁÔ²a¦³Ü:Æ`][w 1/#3),1#0*"`][w4+#4)3#2*"¿Ù0/#0),0*E6CB!
-Á®¦³ÜJÆ`][22#2),.#3*"`][w4+#4)3#2*"¿Ù1+#1),0#
2*E6CB!®á./á·4áHÄXÀPB:ÄáI¾ÖJÆ`][w.á"`][w,á"¿Ù0áE6CB!
G& P6-*+/D>H8A"PNET EX.O9;G$210TVM3JNW!5G$KJNW

ý´Ï±.4V%?S¤îdÊë¸6H×?S¤À´IhH?S

62<QHéH"¼x±.H41D`[YLê(¯H×?SÚ0p}.ÿI±.

aZ_cIyá6UTA!;TJº+Ú0p}.ÿH*1D1A thiotepa Iðíß¬Hï
2OIE0R";THPRÚ0p}.ÿaZ_cJ Topotecan%Topo&"cyclophosphamide%CY&"melpharan%Mel&5QGSÚ0p}.ÿHÞ7~3QTA!Topo$CY$Mel aZ_cû!
I`[YÉu¸4PL PNET J*+3E*.X"ÒdÌÔ-J/+'.(E0BA%È-&4$

Topo!CY!Mel ,*+-'8>.0=:)1&%"#?(5/3!PNET (;2967<!

"!I$âJý´Ï±.4V%?S¤îë¸6H×?Sý´Ï¤À´IeÐÊF%ÊVÂ?S;FE0S!2¿H49S¤îÁ3IÁ3¹ÎJ¼x±.IËòFÅ160R"¼x±.6ØVÄxTK©qÁ36ÙSsFGS!!®EJ®zªPRÁ3
ä56ÎORVoxBA6"¶ASlJå|H49S¼x±.I±.Ës6ØVÚ78ÄxBA;FHPSF3QTS!èHµvâ,&HPRÚ0p}.ÿaZ_cV
topotecen V¶ÖF?S^Wb\]aZ_cHû>Df"¨JÜ1OII`[YI*.X"ÒdÌÔ-6/+(Fn>Ä:QTAs"¤îÁ3H×?S!IÁ3¹Î6'ÑVoxSsFGBA!>5>G6QéHJä5Á3IÕHO"ÐÇý´ÏÀ´Iæ{éì·¤îV+>AÆu¸Á3H×?Sý´Ï¤À´%¤À´Ï0,)Gy&VeÐ5C%H«E7A©Á3O<T"eÐÊHC1DkáIÝ6çQTA!
kþ"Memorial SloanKettering Cancer Center I Baskt QJ"*,3I¤îÉu¸Á3H
×>D¤À´V1"%hG÷§*IÒqG8/G±.s6çQTAFü

>D1S!

*&

Toront Ú}I Bouffet QJ"*.3I¤îÄi¸H×>D¤À´V1"tIô¤À´Á3
Hó>D'6/E0R"øÁO)ñgE0BAFü>D1S!<QH¥½¯r+&

1jEJ"ú¡ St#Jude ½¯öm5Qõ»`[YI¤îÉu¸H×>D¤ý´ÏÀ´6%
E0S;FV²¢?Sà®s6ü

<TD1S!MA!Fù>DUTA³3,&

Iþ­âwÍEO×ÀI"ÒdÌÔ-FÐÌÔ-I£JU@5E0R"¾G8FO¤î
I¦6çQTD1G1;FJ#Q5FGBA!°ãE!J×ÃÁ36¾G16Á3¹
ÎVÓ9G6Q$âÛËVN=>DVÓ?S'áE0S!

3 O m  C / I G

63! $ # "
_[B10>D"cnl?Dvu3tA5XA^DJM>0A0!929A3J_[Cv@:Lsk{Tp"wPpCebCbD]H>?/KAmD`r8M>0A0!uq}CRNzL;HBi~\_[ECWNZH>SdNzK==_[SC|NzK;0!fbBjaB7UN0;<4A7h

QN0;<4F9;3OqYm_[gCVBxoy9w6F:!
&%'$Bakst RL, Dunkel IJ, Gilheeney S, Khakoo Y, Becher O, Souweidane MM, Wolden S ;Reirradiation for recurrent medulloblastoma. Cancer *.,,%*.-("(&''#($Bouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, Tsangaris
E, Huang A, Kulkarni A, Mabbot DJ, Laperriere N, Tabori U ; Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol
Biol Phys '+*'%'+*-"(&'(#)$Wetmore C, Herington D, Lin T, OnarThomas A, Gajjar A, Merchant TE. Reirradiation of Recurrent Medulloblastoma : Does Clinical Benefit Outweigh Risk for Toxicity?
Cancer#(&'*#

$"#!*&(')+%!

TÆOF,*þ5,+d´ØFNE;"
@

º

511½

/

5

,

511½

/ 216

216~ý*ÀÓUwrj{+

ÀÓ%Ö&
?,
"

26

21

¡©Usol|dD¹?TÏ#Ý<?¥~Uø?½#¢ç>RM>;*-?R+d?
;#-9BSüôUÙS=Ê@E;"26S31½/31«PF!«dO@aLA:
ANux|qfhqFNE;"YK#CD-ROM#DVD-ROM ù*pinq¿1ä+d¹?Ä#otq8d9TÏÉS=á`E;"#>'TË'8*,+Uè,½#8#$8UÌ,½O²E;"$

×½U¸?×½d?;#öC¬ìU CGS ìO m#cm#mm#cm3#ml#l#dl#kg#g#
mg RQPFNE;"%

ÀÓUÃµ~ÏTè@EOß9O:aCP#,½]=d®HaÐ¯Uqz'm|kv's'd>AKÏS9FNE;"&¡©U¡âPFN0;KFYIe"ÀÓ#ÖRQO0d@Ha\TSUJTº9F
NE;"

'

,U5,ðS

?EbK\TTZd:BNE;"5,ðT

?£ÈSU

%®d)F

NE;"
(

,TÊ@2U¾T^<SúFNE;"?,#ñÂ8U4ÕYOF#Jb~ÏU,å,et al-PFNE;"
°,T²¿U Index Medicus È²SÆGNE;"¶¼TÐ¯0?%®+ñÂ8&F,ê8#¶¼8#×#.×*ÚEÿ®+ì«5TÐ¯0###.#"«È8#"«?%®+ñÂ8&F,ê8#Ê8*/Â8+

ï#*ÚEÿ®+
D

Í#ó

&219
:#å&TA3$PA3 7*23+

3+7ý(#òëÞ!#·³

Ò&±4TàÔí3$hgyn>_±

2+õ¦Gî#¤¨.225#2981$
4X*+*

Ñ/+#é3##419(438#PA3Á#÷#2983$

4+Umezawa H, Aoyagi T, Suda H, et al : Bestatin, an inhibitor of aminopepitidase
B, produced by Actinomycetes. J. Antibiotics 29 :97.99#2976$),ûU#UG[SOUGY`#=c`SOW"*

F,U@º.UG[S.*æÎ.23.ØÛ+.ª}.=c`S.,.&.ÖTÜ9.
ÖTÇS¡©d§ØFNE;"Ö=^V&SU,ðSÅaÇ%S%®d)FNE;"+­;U¾T^<R®d?;YH"
-$

,

))2$

))2+

))a

¡©SU&»d)F#&ê#ñÂ8#Èã#8#¡©6×#Ö&ô×d9FNE;"

#-&%()'#.!,$+*"%+*%ªò¾6)#S²BýBß$Çz)#éAÊ²Bï:?B_O$#%C$Ãñ

6¯#Îë²B2Bß$¯Ä*ø#1¸`,-.0/"$>ÉÂ)#Ä²B2Bß$@Í#oÿîd<Ù8$Ef~Õ¡#ÇP²B2?B_O$¤í¡#}Æ²B2Bß$òëJNø#S²B2Bß$ÈN#Û#¾t²B2Bß$äþ¸Ï#ÇA²B2Bß$

ÞÁ#²s²B2Bß$LÄ

#PÅ²B2Bß$

ö3ªò¾6)#S²BýBß$3®

÷Û#PÅ²B2Bß$#&C$A(î³v)#Çé²B2Bß$d@#¿²B2Bß${Ä

Yv#XÒ²B2Bß$»¤

Ö#éAÊ²B2Bß$
j·#S²B£°èe2B_O$

%+*&

w
õÄ

-Û#ÇPÅÿTpÙ8$ma´÷L#¨ù²B2Bß$

ÓI#²sÜÿ

Ù.0/"$

ç#îd<²B2Bß$

#Çé²BkxRÙ_O$Æ¶Û#ÇP²B2Bß$ÒÉë

ð·#1¸2?²B$r©·#éAÊ²B2Bß$.

²#Çé²BkxRÙ_O$Ä

¼K#ÇPÅÿTpÙ8$vg

ôÛ#m¸2?²B$¹Ä

Z6#S²B2Bß$¥7

Nó#[+K²B2Bß$#'C$ñ®

4)#;w²B2Bß$Vò

×#²á2?²B$cn×#wü2?²B$

mN

yì#ÇP²B2Bß$

M

Þ×#Çé²BkxRÙ_O$ú&9)#ËÆ²B2Bß$¤âÂ)#Çé²B2Bß$ò®

0Û#oÿÙ8S,-.0/"$Éc²Ö#²s²B2Bß$«Äl#Uë²B2Bß$

vQ

#N!ã²B2Bß$µÌ

#uê2?²B$%+*'

wëvHÛ#S²B£°èe2B_O$
%+*(

²¤

n#S²B2Bß$ò~Û#ÇPÅÿTpÙ8$#(C$¦Ä

Wv#;w²B2Bß$/ë5bL#ºÑ²B'2B\$

½

Y¬#S²B2Bß$

Eq,Ú#oÿ,-.0/"_O$m]¢#Uë²B2Bß$

!Ä
c

%+*)

÷#éAÊ²B2Bß$±D#oÿÙ8S,-.0/"$«w

F#¿²B2Bß$wÄ

6¡#îd<²B2Bß$^w

Û#[+K²B2Bß$

#iÆ²BcÔåÐ2B_O$ÀÕ"#G_!G=B%æ.0/"$à¤$#1Ø²B2Bß$û

·#ÇP²B2?B_O$é®

h×#²s²B2BßÝ­G_O|§$

&+*'

¯]

ÃÙ$F3EÓJ%$'M%"/!*$~7,-.0/#%
àÚÃö$~7,qBô7i<ô.0/#%¯;

6$\3EÓJ%Èæ÷?$fÓJ3Jû%ÜÏ

5æ$a¤ÓJ3Jû%ÚÑÞ$ü43EÓJ%¹)p{þ$ÛÓJ3Jû%pà$`ÔÓJ3Jû%äà°:$ÓÓJñÄýômX¬%"Æ

)×$]n7,-.0/#mX¬%±ÖGÄ$ãYá7cô7%

r¿¥5$~7ô73:.0/#%

Uàt½$õ±3EÓJ%ê0

½$YáÓJ3Jû%Ó0

9$,qBÓJ3Jû%$(M%Aû

Ý?$ãYÓJ3Jû%ÿ0lì$Om!OCJ:$.0/#%

Z5$ãYÓJ3EJmX¬%

&+*(

0

&+*)

/Ñ

oP$a¤ÓJÄÒ&r3JmX¬%

V!àÝ>$gBT©ÓJ3Jû%d)=-$(3EÓJ%4!¸$ãYá7cô7%¡bÍ?$èâÓJ3Jû%àÚ¸×$ãYÓJ@3ñÄýmX¬%àÚ

hÃ$NÅ3EÓJ%Åà

Sö$_RÓJ3Jû%[)´$gBT©ÓJ3Jû%8Ä÷ö$ãY­3EÓJ³CQô.0/#%õA6ì$ÓÓJ3JûúÐOmXÇ%Ìà

D?$ÜÓJ3Jû%[¦¾$äàJ>!k;ÄÓJ3Jû%Óºwì$AÓJ3Jû%¯°ö$É4n,-.0/#%Dä?$ÓÓJñÄýômX¬%$)M%?Ñ

&+**+$uâÓJpð#í3JmX¬%

v$«ßåÓJ3Jû%

2$ÛÓJ3Jû%®²¸ó$èâÓJ|ÎEJmX.0/#%`Ôzë$¹KÓJ3Jû%)ª5$2Øn,-.0/#%ä£$2Øn,-.0/#%=/*?$ã'ÓJx^ômX¬%})$ãYá7cô7%çÝ$uâÓJpð#í3JmX¬%ÚÑ¾¸$ÓÓJñÄýômX¬%ÃAÞ$Óù7Á½ô.0/#%±)e$ÓÓJ3Jû%W"!$'IæÓJ3Jû%s%$É4ÓJ3JûïOmXÇ%Uà

AH$¹KÓJ3Jû%§·5$âÓJ3JûúÐ¢CmXÇ%Ë0.8$ãYÓJ3EJmX¬%ÕÄ$Yáù73EÓJ%A»T$Óù7Á½ô.0/#%µàÂ@$gBT©ÓJ3Jû%

yä

À

¯Ê

Zw$}Ø3EÓJ%Là

×$uâÓJpð#í3JmX¬%¼é/<$YáÓJ3Jû%¯më$§àÓJ3Jû%ä

Ã×$ãYÓJ3Jû%6ó$ü43EÓJ%$*M%1û

¨$wÌÓJ3Jû%jkó$a¤ÓJÄÒ&r3JmX¬%ÖÊè9

Þ$~71&;ÄmX¬%ø9î¶Ã$õ±3EÓJ%þ0$\3EÓJ%k$ãYá7cô7%
Ãò$äàJ>!k;ÄÓJ3Jû%

&)()

/¸

@)#Ò\ÀG2Gì$²µ*#c÷ÀG2Gì$v#ö2BÀG$O8{#Àè"¬©å,.-"$¤Î%#0Äi*+,.-"h[$½Î

sq#0äÀG2Gì$>Î¨#øk?"ÀG2Gìî2Gh[$µÕþ#ÀÀG2Gì$Iµ.ç#Y#ðÀG2Gì$AÓÄx#0Äi*+,.-"$`ùß#}"*+,.-"å5$±Ó0ûØ#=æ"ÀG2Gì$z¤ÿ4#ÖÑÀG2Gì$Æ¼

#Ò\Ï"b~å5$

Ó÷V#zÄ2BÀG$ÇÎPYþ#^2BÀGº|2&,.-"$¡ü®S#ÒõÀG2Gì$w3

Z÷

qÃ#dÞÀG2Gì$#)L$3&))%#&%L$Úü
¹&))&

ñù#0Äi*+,.-"$
#yµ2BÀG${#ÖÑÀG2Gì$ß#^2BÀGº|2&,.-"$;Ónç#Ò\2BBÀG2Gìê»å5$«

ÌÕ#\ÏÀG2Gìê»å5$

ûÂ¢ç#ÀÀGâ¯íåh[$ÅÎt#ÍÔÀG2Gì$ÑÊ

Yù#ÑÀG2Gì$ÎÆ$4#¦JÀGÝh[$Ð]

4e#Ë\ÀG2Gì$ÆÑ¶#øk?ÀG2Gì$¦Êÿ)#ö2BÀG$°¼¿#aÀG¯¾ôm2Gh[$F¯:#ÒDÀG2Gì$j¥Û#}"å5a*+,.-"$

Ó÷

úÃ#0Ä2BÀG$·jPã#aÀG2Gì$ªÂ

S#}"2&h[,.-"$

X

R#aÀG¯¾ôm2Gh[$1Óç#0Äi*+,.-"h[$+#¥ÀG2Gì$

c¥ç#rÑÀGjàòÜ2Gh[$£ï#zÄ2BÀG$AÓû¼q)#Ò\2BÀG$Cü

ó#QéÀG2Gì$(û-#pÀG2Gì$ÎÆ'ù#Ò\Ï"b~å5$

ï3

YM#Ò\ÀG2Gì$§Tu#Àè"¬©å,.-"$#&&L$µ9Ó8"#ö2BÀGê»*+h[$ÿ#Nh!Nh[$o#Àî2BÀG$áÑþ#Ù÷ÀG2Gì$×

#øk?ÀG2Gì$p­#\Ïè"2BÀG$ý'Ø)#øk?"ÀG2Gì$³Á

l#^i"*+,.-"$

sÛ#}"*+,.-"Æ<å5$#&'L$Ej¥ù#ÉÀG2Gì$

g¡

$Û#È

C¼

7Ø#õ!h[å5$WÅ

f#!e,*+,.-"$

û÷

1ã#ÀÀGâ¯íåh[ê»å5$KL/#õDÕÀG2Gìê»Nh[´$_6'ã#\ÏÀG2Gì$Ó

U¯#Àî2BÀG$0ëSþ#`ÁÀG*+h[$´H¥x#Ò\Ï"b~å5$Î#¦JÀG2Gì$

Ð3

&))'

ÀG2Gì$

#Àè"¬©å,.-"$

%++&³>#êa7GGÔO7O!$

ÃÎ{#êMÔO7O!$#%&R$CïG

ª|#dÕÔO7O!$]NÓ³#5tBÔO7O!ùÒ»wo`Æ$%++'H#"èpC7GÔO$ÔS

ÓE#AÔO7O!$#%'R$(nN#Â23.417GÔO$/è

½¡#jO[¦ÔO7O!$

gs

4#±MÔOþÍ-¤ù;$®Ú

L#Wo!Wo`¬$q

ô#àaÔO7O!$

5!

>ä

Á±#aæýC7GÔO$ÿYð#/MíÔO7O!þÍWo`Æ$ÖÎçä

F±#êaÔO7O!$

u8

JM#êaæCfù;$üäTû#cpC,-/40"o`¬$ÜÎ

b9#êa7GGÔO7O!$

Rä?%#Wo!WDOF+/40"$&Aá#ÔýC¼¸ù/40"$&A¶S#aæÔO7O!$

0­[#ê/ÔOEJ7Oo`¬$]ä²ð#5tBÔO7O!ùÒ»wo`Æ$Ë<

iK#Wo!WDOF+/40"$

Úä

L#C,-/40"Ü?ù;$#%(R$Î¾ñ#aæÔO7O!$

AäÉ#e¢ÔOÀÑ.w7Oo`¬$ÅPÁ9#ê/ÔO7O!$\Ù]#17GÔO7O!$®<

Øø#/MíÔO7O!$º2

â#_7GÔO$¿7r#dÕÔO,-o`¬$äÜn9#´QÔO7O!$

ßØ¡#5tBÔO7O!þÍù;$´äÓ#«ãìÔO7O!$úzí¼#5tBÔO7O!$²

;#ÛóÔOI°7Ol$

ë2£9#Ç@p,-/40"$<Q±û#Wo!Wo`¬$¨¡#è7GÔO$

%++(

%++)

A2

¯#5tBCÔO7O!$7Oo`¬$#%)R$ëÝöt#Chù;$

%++*

]ä
vë

#MHpC7GÔO$Ê#êaæCfù;$¥Ì#àaÔOÀ#}Oo`/40"$ë|#àaÔO7O!$éä#@úCÔO7O!$

ä

S#jO[¦ÔO7O!$

äÜyû#~èÔOsõ*ò7Oo`¬$ÜÎ#ÞÔO7FZ§×XÔO!$I8

#ÔýC¼¸ù/40"$

ëä©#aæÔOÔO;7Oo`G$

36¾[#dÕÔO,-o`¬$U:µ

6L#êaÔO7GOo`¬$<È

T#e¢ÔOÔO;¹BOo`G$MP

îû#e¢ÔOÀÑ.w7Oo`¬$=8¡#aæÔO7Oo`G$ÄÈ#ÔýC¼¸ù/40"$

bx#^D'ÔO7O!$ÔÈ#%*R$6ê
®Q

k9#7GÔOm=7Oo`!8$8ë;#ê/ÔOEJ7Oo`¬$:º2,9#Wo!WDOF+/40"$

ÖÏA÷ML#·ïÈpC,-/40"$²Î

ô#7GÔO7O!$

û#ÛóÔOI°7Ol$¾ø#VÃåHù;$ÐL#

Ø7GÔO$

nK#êaÔO7GOo`¬$)~#C,-/40"Ü?ù;$

&++(

M

\

²1#~I;GÆN;Nø$´±#vÞÆN;Nø$ZÂ¨ï#[6üÆN¸*GNi]¡$¹AÓu#}5,0475"i]¡$°ÿ

t=#&;GÆN$#&)P$³m

FÆ#8Ðj,0475"i]¡$ÙÒ

Jó#eÆN;Nø$Ìn=#}5q@¸>ANø$Þ¨#ÆÆN;Nø$Ò¼lª#»3j,0475"$-ÙÖ¸#Si!Si]¡$%<+#ß$ÆNÆN>;Nhi]G$©

0#ß^ÆNÆN>;Nhi]G$£ë#}5,0475"ÒBð>$?-7ë#Æô5´±ð475"$~à¦#&;GÆN;Nø$ÒÞ¥#}5ð>e,0475"$

#&(P$
&++)

&++*

?

#&*P${nÊ&+++=#Æú;GÆN;Nø$0#9¼;GÆN$×æ#Æ5ÆN;Nø$)¼

w=#ß^ÆN;Nø$Ûêl¶ñ#ß^;GGÆNäRi]¡$

í·ï#;GÆN$þ#ÆN;Nø$òé¬>#8Ðj,0475"$½Ë

#Ø4./-¾Ï¡;Ni]¡$Â<¢#g@YÆN;Nø$:kq¶#a;GÆN;Nø$.

7ó#Si!SDN8"475"$<«ï#ÆÆNÆN>$Æ«

iå#ßKÆN;Nø$#&+P$ÆÇ

#vÞÆNlì!ç;Ni]¡$

FIË/z#vÞÆN;Nø$H«

0#g@YÆN;NøºÍ;GNi]¡$¯L

2=#^ÜÆN2163i]¡${Ö#&;GÆN$ÙÒ

#$KáÆN;Nø$ÝÙ¶À#­OÆN;Nø$-Ùµ#ß^;GGÆNäRi]¡$(Å§W#^ÜÆN;Nø$sÙ

Ô#dÈÆN,0i]¡$®?

[7#UõÆN;Nø$

ZX

ÉQ#I;GÆN$¶#dÈÆN;Nø$C-·7#cVÆN;Nø$ûó#}5f'ð>$°ã,¯4#ß^;GGÆN;N¿|i]G$[ÿâ#g@YÆN;Nø$£¹

û1#;GÆNÆ\;8475"$~àë#dÈÆN,0i]¡$ÙÒ

y=#^ÜÆNÆN>$î-`ó#Si!Si]¡$

ÚC
'%%%

<«

#'%P$H-Ò-

#eÆNÆN>$ù'

N#ß$ÆNF<;Ni]¡$©ÂrEæ#vÞÆNlì!ç;Ni]¡$

Z¼

#ÆÆNÆN>$Ã#Si!Si]¡$ßû#g@YÆN;Nø$pÎ#eÆNÆN>$£:}ï#bj5,0475"$

BÕ_Tv#~I;GÆN${_#ß^ÆN;NøöÁð>$Ùlb,

Ó9#$KáÆNÆN>$

ZÙ
'%%&

÷#eÆN¸Ä#o;Ni]¡$#'&P$ý-+#ÑèÆN;¤;Nh$Ðæ#ß^;GÆN$x#ß^ÆN;GNi]¡$

'%%&

ã

#'&P$;ìÒK£Ä'%%'Â#ÙrBÞ@";$ý#ÕÕMÿÊ("q`±$Î#íb²6FÕMùÀo021"$

Þì

L#^C-ÕM6M&$¹µ¼#h¦ÕM6E[­ØVÕM&$6

ý#56FÕM$
Î=#H6FÕM$

Ã#B./021"q`±$©è®#3JðÕMÕM;$?î

#''P$O;®X#°çïÕM6M&$³ÍKJ#3AÕMí";$ÆD#Ì6FÕM$cm:#íbêBi";$yè

Èý#mM\¬ÕM6M&$

Ac

1#gÖÕM./q`±$+âÈ#Õ$BÅÁ"021"$º6»õ#«ÕM6M&$³;I#ÝúÕMH´6Mn$#'(P$Àè

Î»#íbÕM6M&$

vSG;

õ#@ÕM6M&$

Ä

'%%(

k÷#Õ$BÅÁ"021"$

4|=#mM\¬ÕM6M&$

å#U¤6FÕM6M&$+7

##Tq!Tq`±$ìÕM";$

G;E)# ìÕMÕM;6MÏq`F$

k÷#Tq!TDME0021"$:#h¦ÕM";$èÞ)k#bêÕM6M&$

Þì¯#mM\¬ÕM6M&$

w×K^#4Ùr./021"$Ç¿È¥#h¦ÕMÊÔ2z6Mq`±$6

j×·8#BÅ86E021"$

ø

à#5GÕM6M&$#'*P$Lë

æ~#íbÕM6M&%Ñ";$ëC#gÖÕMÕM;$,9

Q##gÖÕM6M&%Ñ";$üu:#e6FÕM$ß×Ì}Y#7wCÕM6M&%Ñ";$<ÊÕZ#ÕBÕMÕM;$G½:#í3ÕM6M&$

ö;I÷#ÕBÕMÕM;$Í6§:#ÕÕMÕM;$7ºk#ÙÕM6M&$

ñ#fWÞ@d&¡R021"$

Õí8#Õ$BÅÁ"021"$³G#òFrB6FÕM$«#íbêBi";$Nè8^#Õ$B/.pÏ6E021"$

ÜóÐ#Ày6E021"$'B

K:#*x6FÕM$î7

ÈÁ#íb6E021"$º;É»#Õ$BÅÁ"021"$

'%%)

ôu

¸!#ö66FÕM$aª#')P$É_

'%%*

'%%+

#'+P$Óè

'%%,

96

{#

:#ßÕM6M&!M&%Ñ";$#',P$ûCup#Tq!<8";$'%%-Ë#lrBÞ@";$¶#B./021"Þ@";$á7¨:I#íbÕM6M&%Ñ";$¢=»ä#íbêBi";$¾Ú

?÷# ìÕM6M&!M&%Ñ";$s¸F#gÖÕM6M&%Ñ";$;

3w#B./021"Þ@";$NÚ]#h¦ÕMÕM;$þ×>¥#7wCÕM6M&$?÷#ìÕMÕM;$Üì¼~#Tq!<8";$¹Ò.#B./021"í";$t>

F#gÖ6FÕM$]Û:#gÖÕMÕM;$éO

·!#3AÕM6M&$#'-P$¾Ú'%%)¨,*-#\´GÏ7$#')I$!À

'%&%¤p#¹É´G´G7$º¥«Ç#´3ë/10"$

e#ÄU´G´G7$ÔÓÜÀ

nî#ÄUÁè]Ï7$SÀÄ§#´3@´G$­¯CÈ#Æìiè3@´G$

¦6#®å´G´G7$¶

ò#ïAiè3@´G$¼À

z#aðP´G3GÓ$Åk

PÈ#´´G´G7$

q

ïá#MÒ´G3GÓ$yq:æ#´´G´G73GchT@$Q¸

9#aðP´G3GÓ$²6#^Ê´G´G73GchT@$Å¶ï«#èÏ7Nx´3ë/10"$#(&I$½

'%&'

{â

»¶¯

#(%I$

'%&&

bP#MÒ´G´G7$

Ù#aðP´GãGÓ$Ë#´´G´G7$|#UÁÑè3@´G$Ü~«Þ#´Ñè©§Ï/10"$

SÀ

vr#»

SÀ

Pz#uÃ´GkÌØ°3@GhT$

j4

ÂÎ#ÄÚ´GÏ7$?

d#Úç´G3GÓ$8Ü

ê#Z3@´G$

H¬

ïË#L3@´G3GÓ$Å

v#Û3@´G$#('I$¬O#+.hTDäÞÏ7$

´GÏ7$

ñà

«s#2·i+./10"º;Ï7${X¿#´Ñè©§Ï/10"$¶<¦#Õmiè+./10"$

ÜJ#ÄUÁfv»3ë/10"hT$¡àEç#aðP´GÏ7$³¢:#[µ´Gª`F@$

4¢_#{·´GW5hTÓ$=:#\´GÏ7$#((I$B}

gv#Ýl>è´G´G73GhT@$ÚY¯t¿#´´G´G73GchT@$À¾í#RéÖ´G3GÓ$Ã

ßÐ#[µ3@´G±}3GhT$³

Vw#o3ë/10"!º+./10"$

â£×#Ýl>è´GÏ7$KX

Í#´Ñè©§Ï/10"$'%&(

#aðP´G3GÓ$7Tx¨E3LI+,`*/+l*- [w*/+l+) r

"

!

#

r p\u

7T|_x¨ngut x }5£4sR=F]dD5a44>;H<!
')+.&((/) iqjeo)&*0&.
UVWX+2-.*/&/-1+©$(+%[w Yk[w¡E¥EZ3P4FS¢A"ycb46CP
DM?@Ky#<P9BF"§AJNQ>sS
8"v{5MG~{Em¦E ^DCOH<EA"¤JzEhSfJ@]:4!